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(57) ABSTRACT 
Methods for treatment and/or prevention of nerve degenera-
tion in mammals using aza-peptide epoxide caspase inhibi-
tors are provided. Aspects of the present disclosure include 
aza-peptide epoxide compositions to treat or prevent dis-
eases, for example stroke, Alzheimer's disease, Parkinson's 
disease, multiple sclerosis, neuropathies, Huntington's dis-
ease, dentatorubropallidoluysian atrophy, spinocerebellar 
atrophies, spinal bulbar muscular atrophy, diabetes, amyo-
trophic lateral sclerosis and other motor neuron diseases. The 
disclosed methods can be used in combination with calpain 
inhibitors to treat disease or pathological conditions related to 
the activity of caspases and calpain associated with a specific 
disease or condition. Such treatable conditions include 
stroke, Alzheimer's disease, Parkinson's disease, multiple 
sclerosis, neuropathies, Huntington's disease, dentatorubro-
pallidoluysian atrophy, spinocerebellar atrophies, spinal bul-
bar muscular atrophy, nerve degeneration associated with 
diabetes, amyotrophic lateral sclerosis and other motor neu-
ron diseases, nerve degeneration secondary to primary demy-
elinating disorders, among others. 
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1 
AZA-PEPTIDE EPOXIDES 
CROSS-REFERENCED TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of U.S. Utility 
patent application Ser. No. 10/603,054 entitled "Aza-Peptide 
Epoxides,"filedonJun. 24, 2003 now U.S. Pat. No. 7,056,947 
(which claims the benefit of U.S. Provisional Patent Applica-
tion No. 60/394,221 filed on Jul. 5, 2002, U.S. Provisional 10 
Patent Application No. 60/394,023, filed on Jul. 5, 2002, and 
U.S. Provisional Patent Application No. 60/394,024 filed on 
Jul. 5, 2002) and of U.S. Utility patent application Ser. No. 
10/671,360 entitled "Ketoamide Inhibitors in Chronic Nerve 
Disease," filed on Sep. 25, 2003 (which claims the benefit of 15 
U.S. Provisional Patent Application No. 60/413,506 filed on 
Sep. 25, 2002), all of which are incorporated herein by refer-
ence in their entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
20 
2 
from Aspergillus japonicus by Hanada et al. in 1978. The 
chemical structure was determined by optical rotation, NMR, 
IR, MS, elemental analysis, and amino acid analysis to be 
N-(N-(L-3-trans-carboxyoxiran-2-carbonyl)-L-leucyl)ag-
matine. Hanada and his coworkers showed that E-64 would 
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Once the E-64 structure was elucidated, the research 
groups of Katunuma, Barrett, and others discovered E-64's 
inhibitory potency toward a large number of other cysteine 
proteases. E-64 inhibits papain, ficin, bromelain, cathepsin B, 
H, F, K, L, 0, S, V, X, calpain, calpain II, cruzain, and other 
Aspects of the work described herein were supported by 
grant No. GM061964 from the National Institutes of Health. 
Therefore, the U.S. government has certain rights in the dis-
closure. 
25 cysteine proteases. Cathepsin J and streptococcal cysteine 
protease are slowly inhibited by E-64. 
BACKGROUND 
Unlike many other microbial inhibitors, E-64 is a potent 
and specific irreversible inhibitor of cysteine proteases, and is 
used as a diagnostic reagent for identification of cysteine 
1. Field of the Disclosure 
This disclosure relates generally to protease inhibitors and 
applications thereof, more specifically to peptide inhibitors of 
cysteine proteases, even more specifically to aza-peptide 
epoxides, methods of their use, and methods of their produc-
tion. Other aspects of the present disclosure relate to the use 
of the above compositions for the treatment of neurodegen-
eration and conditions associated with neurodegeneration. 
30 proteases. The compound E-64 does not inhibit serine pro-
teases, aspartic proteases, or metalloproteases. However, not 
all cysteine proteases are inhibited by E-64. Examples of 
non-inhibited cysteine proteases are legumain and caspases. 
Caspases and legumain are members of the CD clan of cys-
2. Related Art 
35 teine proteases, while papain, cathepsins, and calpains are 
members of clan CA. The following table lists those enzymes 
which are inactivated by E-64 and those which are not inac-
tivated. 
Protease inhibitors are important therapeutics in the treat-
ment of a variety of disease conditions including viral infec- 40 
tions such as HIV infection. Proteases are enzymes that 
cleave proteins or peptides and are classified into several 
groups. For example, cysteine proteases form a group of 
enzymes involved in numerous disease states, and inhibitors 
of these enzymes can be used therapeutically for the treat- 45 
ment of diseases involving cysteine proteases. 
To date, a structurally diverse variety of cysteine protease 
inhibitors have been identified. Palmer, (1995) J. Med. 
Chem., 38, 3193, discloses certain vinyl sulfones which act as 
cysteine protease inhibitors for cathepsins B, L, S, 02 and 50 
cruzain. Other classes of compounds, such as aldehydes, 
nitriles, a-ketocarbonyl compounds, halomethyl ketones, 
diazomethyl ketones, (acyloxy)methyl ketones, ketomethyl-
sulfonium salts and epoxy succinyl compounds have also 
been reported to inhibit cysteine proteases. See Palmer, id, 55 
and references cited therein. Many irreversible cysteine pro-
tease inhibitors have been described in the review by Powers, 
Asgian, Ekici, and James (2002) Chemical Reviews, 102, 
4639. See Powers, id, and references cited therein. However, 
most of these known inhibitors are not considered suitable for 60 
use as therapeutic agents in animals, especially humans, 
because they suffer from various shortcomings. These short-
comings include lack of selectivity, cytotoxicity, poor solu-
bility, and overly rapid plasma clearance. 
In addition, epoxides also have been shown to inhibit cys- 65 
teine proteases. The first epoxysuccinyl peptide discovered 
was E-64, a natural inhibitor, which was initially isolated 
Enzymes Inactivated or Not Inactivated by E-64. 
enzymes inactivated rate (M-1 s- 1) enzymes not inactivated 
fie in 0.084 (ID50) trypsin 
fruit bromelain 0.110 (ID50) a-chymotrypsin 
stem bromelain 0.025 (ID50) kallikrein 
papain 0.104 (ID50) pepsin 
cathepsin B 89,400 plasmin 
cathepsin H 4,000 elastase 
cathepsin L 96,250 Mold acid protease 
cathepsin K 1.8nM(K;) LDH 
cathepsin S 99,000 thermolysin 
cathepsin X 775 collagenase 
cathepsin 0 > 100 µM (ICso) clostripain 
cathepsin F caspase 1 (ICE) 
cathepsin V >0.1 µM (ICso) legumain 
cathepsin J 
DPPI 100 
streptococcal proteinase 624 
papaya proteinase N 58,000 
calpain II 7,500 
bleomycin hydro lase >160 µM (IC50) 
cruzain 70,600 
vignain 32,500 
Therefore, because of the aforementioned deficiencies in 
the art, there is a need for new compounds and methods for 
inhibiting proteases, in particular cysteine proteases. 
There is also a need for compositions and methods for 
treating nerve degeneration in patients, particularly since 
US 8,013,014 B2 
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peripheral neuropathy is a major dose-limiting complication residues in the Pl site. Such aza-peptide epoxides are potent 
inhibitors of caspases. Aza-peptide epoxide caspase inhibi-
tors are useful for the treatment of stroke and inflammatory 
diseases, and as inhibitors of apoptosis. Thus, another aspect 
provides a method of treating stroke, inflanimatory disease, or 
inhibiting apoptosis including administering an effective 
amount of a aza-peptide epoxide to a patient in need thereof. 
Such patients can include any mammal, for example a mam-
mal exhibiting symptoms characteristic protease related 
pathology or disease condition such as stroke, inflammatory 
disease, or pathology related to apoptosis. 
Another aspect of the present disclosure provides an aza-
peptide epoxide composition containing an aza-asparagine 
residue at the Pl position. Aza-peptide epoxides having an 
of commonly used anti-cancer agents, including vincristine, 
cisplatin, and paclitaxel (Taxol®). Paclitaxel, a microtubule 
toxin derived from the western yew tree, is particularly effec-
tive against solid tumors, but causes a predominantly sensory 
neuropathy that may be severe enough to necessitate cessa-
tion of treatment. The neuropathy is characterized by degen-
eration of sensory axons, manifesting clinically as numbness, 
pain, and loss of balance [Lipton, R. B., S. C. Apfel, J. P. 
Dutcher, R. Rosenberg, J. Kaplan, A. Berger, A. I. Einzig, P. 10 
Wiernik and H. H. Schaumburg (1989). "Taxol produces a 
predominantly sensory neuropathy." Neurology 39 (3): 368-
73]. Paclitaxel causes a similar sensory neuropathy in rodents 
that provides a useful experimental model for the treatment of 
peripheral neuropathies. 15 aza-asparagine residue at the Pl position inhibit legumain 
and can, therefore, modulate the immune system through 
such inhibition. Cleavage of antigens by proteases such as 
legumain and related proteases is a step in antigen presenta-
Because neuronal pathologies, in particular neuropathy, 
can have a dramatic impact on quality oflife of patients, there 
is also a need for compositions and methods for treating these 
disorders, in particular, compositions and methods for treat-
ing pathologies with little or reduced side effects such as 20 
neuropathy. There is also a need for methods and composi-
tions for treating axonal degeneration. 
tion including the display of MHC class II peptides. Thus, 
another aspect of the present disclosure provides a method of 
modulating the immune system of a patient by administering 
to a host an effective amount of an aza-peptide epoxide com-
position. The aza-peptide epoxide can modulate the immune 
system by inhibiting the cleavage of antigens in the patient SUMMARY 
The present disclosure is directed to providing composi-
tions and methods for meeting the aforementioned needs. 
Aspects of the present disclosure provide compositions for 
inhibiting proteases, methods for synthesizing the composi-
tions, and methods of using the disclosed protease inhibitors. 
The compositions described herein can inhibit proteases, for 
example cysteine proteases, either in vivo or in vitro, by 
contacting a cysteine protease with an aza-peptide epoxide. 
The disclosed compounds, pharmaceutically acceptable 
salts, pharmaceutically acceptable derivatives, prodrugs, or 
combinations thereof can be used to treat disease or patho-
logical conditions related to the activity of proteases associ-
ated with a specific disease or condition. Such treatable con-
ditions include viral infections, stroke, neurodegenerative 
disease, and inflammatory disease, among others. Methods 
disclosed herein for treating diseases include administering 
an effective amount of an aza-peptide epoxide to a host in 
need thereof to inhibit or reduce protease activity in the host, 
particularly cysteine protease activity, more particularly 
activity of caspases, calpains, cathepins, papain, gingipain, 
clostripain, separin, or legumain. One or more aza-peptide 
epoxides of the present disclosure can also be used alone or in 
combination with each other, other protease inhibitors, or 
another therapeutic agent including anti-viral compounds 
such as anti-viral nucleosides including nucleoside analogs. 
One aspect of the present disclosure provides aza-peptide 
epoxide compositions, for example a compound or pharma-
ceutically acceptable salt or pharmaceutically acceptable 
derivative thereof according to Formula I below. In some 
aspects of the present disclosure, aza-peptide epoxide inhibi-
tors are specific for cysteine proteases and do not inhibit 
serine proteases or aspartyl proteases. In another aspect of the 
present disclosure, these aza-peptide epoxide compounds 
potently and specifically inhibit clan CD of cysteine proteases 
and are also inhibitors of clan CA. Exemplary differences 
between aza-peptide epoxides disclosed herein and other cys-
teine proteases inhibitors include different mechanisms of 
inhibition of the cysteine residue and the binding modes. 
Some aza-peptide epoxides of the present disclosure can be 
constructed to selectively inhibit individual cysteine pro-
teases or groups of cysteine proteases. These aza-peptide 
epoxides can, for example, contain acidic aza-amino acid 
25 and thereby reducing the display of antigen peptides on cell 
surfaces. 
Yet another aspect of the present disclosure provides a 
method of treating autoimmune disease by administering an 
effective amount of an aza-peptide epoxide to a host in need 
30 thereof. The host can be any manimal, including primates, 
which demonstrate symptoms associated with any number of 
autoimmune diseases including but not limited to lupus, for 
example lupus erythematosus, and cancers. 
Another aspect of the present disclosure provides aza-
35 peptide epoxides containing basic residues at the Pl position. 
Such aza-peptide epoxides inhibit proteases such as gingi-
pain, separin, and clostripain. Aza-peptide epoxide inhibitors 
of gingipain can be used fortreatment of periodontal diseases. 
Aza-peptide epoxide inhibitors of separin are useful for stop-
40 ping, modulating, or interfering with cell division. 
Yet another aspect of the present disclosure provides aza-
peptide epoxide protease inhibitors with hydrophobic amino 
acid residues in the P2 site. These aza-peptide epoxide pro-
tease inhibitors inhibit proteases such as cathepsins, includ-
45 ing cathepsin B, and papain. Aza-peptide epoxide inhibitors 
of cathepsin B are useful for treating hyperproliferative con-
ditions including cancer. 
Another aspect provides aza-peptide epoxides having 
small hydrophobic alkyl amino acid residues at P2 are good 
50 inhibitors of calpain I and II. These inhibitors are useful as 
neuroprotectants and can be used as therapeutics for the treat-
ment or prevention of neurodegeneration and stroke and 
pathologies of the peripheral nervious system such as neur-
opathy, axonal degeneration, or calcium-induced cell injury. 
55 Exemplary neuodegenerative disorders that can be treated 
with the disclosed aza-peptide epoxides include but are not 
limited to stroke, Alzheimer's disease, Parkinson's disease, 
Huntington's disease, multiple sclerosis and other demyeli-
nating diseases, neuropathies including those due to genetic 
60 mutations and peripheral neuropathies induced by anti-can-
cer agents, axonal degeneration, metabolic derangements ( eg 
diabetes, uremia) and idiopathic disorders, spinocerebellar 
atrophies, amyotrophic lateral sclerosis (ALS) and other 
motor neuron diseases, and traumatic injuries to the central 
65 and peripheral nervous systems. 
In another aspect, the present disclosure provides methods 
for the treatment and/or prevention of nerve degeneration 
US 8,013,014 B2 
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involved in proteolytic activation of proinflammatory cytok-
ines. Caspase-1 is also involved in the Fas and TNFR apop-
totic pathway. Group II (2, 3, and 7) caspases are late phase 
effectors of apoptosis and are involved in the cleavage of key 
structural and homeostatic proteins. Caspase-3, also known 
as CPP32 (cysteine protease protein 32-kDa), Yama or apo-
pain, is believed to be one of the major effectors in apoptosis. 
This enzyme is a key executioner because it is responsible 
either partially or totally for proteolytic cleavage of key apo-
induced by neurotoxic agents and/or anti-cancer agents. Such 
methods include administration of a composition including 
an aza-peptide epoxide, and in particular aza-peptide 
epoxides having small hydrophobic alkyl amino acid residues 
at P2 and/or aza-peptides having acidic amino acid residues at 
Pl and/or aza-peptide epoxides that are effective caspase 
inhibitors. In other aspects, the methods include administra-
tion of a composition including an aza-peptide epoxide and a 
calpain inhibitor. In yet other aspects, the methods include 
administration of a composition including an aza-peptide 
epoxide prior to or simultaneous with administration of an 
anti-cancer drug. 
In another aspect, the present disclosure provides a method 
to identify proteolytic enzymes and a method to prevent pro-
teolysis. 
10 ptotic proteins. It functions to decrease or destroy essential 
homeostatic pathways during the effector phase of apoptosis. 
Caspase-3 cleaves or activates nuclear enzymes, such as poly 
(ADP-ribose) polymerase (PARP), the 70 kDa subunit of the 
Ul small ribonucleoprotein, the catalytic subunit of DNA-
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a bar graph showing quantitative measure of 
relative protection of calpain inhibitor AK295, aza-peptide 
epoxide JG36, anda combinationofAK295 andJG36 against 
vincristine-induced axonal degeneration at 6 days after treat-
ment. 
15 dependent protein kinase, and protein kinase Co. Group III (6, 
8, 9, 10) caspases are involved in the upstream early activation 
of effector caspases. Studies have shown that caspase-8 and 
10 can cleave radiolabeled precursors for caspase-3. 
Caspase-6 is the only known caspase that cleaves the lamins, 
20 the major structural proteins in the nuclear envelope. Pro-
teolysis oflamins is observed in cells undergoing apoptosis. 
Caspase-8 (MACH/FLICE), which can cleave all other 
known caspases, is suggested to lie in the pinnacle of the 
apoptotic cascade, at least when apoptosis is initiated by some 
DETAILED DESCRIPTION 
The present disclosure may be understood more readily by 
reference to the following detailed description and the 
Examples included therein. 
25 stimuli such as Fas-L and TNF. Accordingly, the present 
disclosure encompasses compositions and methods of alter-
ing, inhibiting, or reducing the formation of enzymatic reac-
tion products involving cysteine proteases. Inhibiting the for-
mation of cysteine protease reaction products in vivo can 
30 provide therapeutic effects to patients suffering from unregu-
lated or 
Before the present compounds, compositions and methods 
are disclosed and described, it is to be understood that this 
disclosure is not limited to specific synthetic methods, spe-
cific pharmaceutical carriers, or to particular pharmaceutical 
formulations or administration regimens, as such may, of 
course, vary. It is also to be understood that the terminology 35 
used herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting. 
Cysteine Proteases. The aza-peptide epoxide compositions 
provided herein inhibit enzymatic cleavage of proteins or 
peptides, or a combination thereof. Exemplary enzymes 40 
inhibited by aza-peptide epoxides include cysteine proteases, 
for example, calpain. Calpain uses a cysteine residue in the 
catalytic mechanism in contrast to serine proteases which 
utilize a serine residue. Exemplary cysteine proteases include 
papain, cathepsin B, calpains, caspases, gingipain, clostri- 45 
pain, legumain, and several viral enzymes. 
Caspases have a specificity for at least the four amino acids 
to the left of the cleavage site (P side). The S4 subsite is the 
single most important determinant of specificity among 
caspases after the Pl Asp. The optimal sequences of the 
caspases were obtained using a positional-scanning combi-
natorial substrate library (PS-CSL). The optimal recognition 
sequences for these enzymes are closely related to the 
sequences found in known macromolecular substrates. 
Group I caspases' optimal sequence is Trp-Glu-His-Asp 
(WEHD) (SEQ. ID NO. 2) with S4 favoring hydrophobic 
amino acids. Group II caspases' optimal sequence is Asp-
Glu-X-Asp (DEXD) (SEQ. ID NO. 3) with a requirement for 
Asp in S4. Group III caspases' optimal sequence is N-Glu-
X-Asp where N=Val or Leu and X can be any amino acid 
( (V,L )EXD) (SEQ. ID NO. 4) with a preference for branched, 
aliphatic side chains in S4. The S3 subsite prefers glutamic 
acid (E) in most of the caspases which could be explained by 
the salt link betweenArg-341 (involved in stabilization of the 
Pl aspartic acid) and the glutamic acid in P3. 
Neural tissues, including brain, are known to possess a 
large variety of proteases, including at least two calcium 
stimulated proteases termed calpains. Calpains are present in 
many tissues in addition to the brain. Calpain I is activated by 
micromolar concentrations of calcium while calpain II is 
activated by millimolar concentrations. In the brain, cal pain II 
is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
potentiation, synaptic plasticity, and cell death. Other Ca2+ 
Caspases are a recently discovered family of cysteine 
endoproteases, which are highly selective for Asp at the Pl 
residue. As a result, this newly emerging family of proteases 
has been called caspases ( cysteinyl aspartate-specific pro- 50 
tease). All caspases contain the conserved pentapeptide active 
site motif Gln-Ala-Cys-X-Gly (QACXG)(SEQ. ID NO. 1), 
where X=Arg, Gin, Gly (R, Q, G), and are synthesized as 
inactive proenzymes. The only other mammalian protease 
with specificity for Asp is the lymphocyte serine protease, 55 
granzyme B. Many of the proteolytic cleavages that are 
observed during apoptosis and cytokine maturation are due to 
the action of various caspases. Indeed, many of the pro-
caspases are activated by other caspases, which selectively 
cleave at Pl Asp residues in their recognition sites. 
At present, there are 14 homologous members of the 
caspase family in humans. Some caspases are important 
mediators of inflammation, where they are involved in the 
production of inflammatory cytokines, and others are 
involved in apoptosis, where they participate in signaling and 65 
effector pathways. Group I (1, 4, 5, 11, 12, 13, and 14) 
caspases are primarily mediators of inflammation and are 
60 activated cysteine proteases may exist, and the term "calpain" 
is used to refer to all Ca2 + activated cysteine proteases, includ-
ing calpain I and calpain II. The terms "calpain I" and 
"calpain II" are used herein to refer to the micromolar and 
millimolar activated calpains, respectively, as described 
above. While calpains degrade a wide variety of protein sub-
strates, cytoskeletal proteins seem to be particularly suscep-
tible to attack. In some cases, the products of the proteolytic 
US 8,013,014 B2 
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digestion of these proteins by calpain are distinctive and 
persistent over time. Since cytoskeletal proteins are major 
components of certain types of cells, this provides a simple 
method of detecting calpain activity in cells and tissues. Acti-
vation of calpains and/or accumulation of breakdown prod-
ucts of cytoskeletal elements have been observed in neural 
tissues of mammals exposed to a wide variety of neurodegen-
erative diseases and conditions. For example, these phenom-
ena have been observed following ischemia in gerbils and 
rats, following stroke in humans, following administration of 
the toxins kainate, trimethyltin, or colchicine in rats, and in 
human Alzheimer's disease. 
Cathepsin Bis involved in muscular dystrophy, myocardial 
tissue damage, tumor metastasis, and bone resorption. In 
addition, a number of viral processing enzymes, which are 
essential for viral infection, are cysteine proteases. Inhibitors 
of cysteine proteases would have multiple therapeutic uses. 
Other important cysteine proteases are the bacterial 
enzymes clostripain and gingipain. Gingipain causes tissue 
destruction during periodontal diseases. Legumain is a 
related cysteine proteases which is involved in inflammatory 
diseases. Separin is involved in separation of sister chroma-
tids during cell division. 
The present disclosure includes all hydrates, solvates, 
complexes and prodrugs of the compounds ofthis disclosure. 
The term prodrug refers to a pharmacologically inactive com-
pound that is converted to an active drug by a metabolic 
biotransformation. Prodrugs include compounds wherein an 
amino acid residue, or a polypeptide chain of two or more 
(e.g., two, three or four) amino acid residues is covalently 
joined through an amide or ester bond to a free amino, 
hydroxy or carboxylic acid group of compounds of Formula 
I. Additional types of prodrugs are also encompassed. For 
instance, free carboxyl groups can be derivatized as amides or 
alkyl esters. The amide and ester moieties may incorporate 
groups including but not limited to ether, amine and carboxy-
lic acid functionalities. Free hydroxy groups may be deriva-
tized using groups including but not limited to hemisucci-
nates, phosphate esters, dimethylaminoacetates, and 
phosphoryloxymethyloxycarbonyls, as outlined in D. 
Fleisher, R. Bong, B. H. Stewart, Advanced Drug Delivery 
Reviews (1996) 19, 115. Carbamate prodrugs of hydroxy and 
amino groups are also included, as are carbonate prodrugs 
and sulfate esters of hydroxy groups. Derivatization of 
hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl 
ethers wherein the acyl group may be an alkyl ester, option-
ally substituted with groups including but not limited to ether, 
amine and carboxylic acid functionalities, or where the acyl 
group is an amino acid ester as described above, are also 
encompassed. Prodrugs of this type are described in R. P. 
Robinson et al., J. Medicinal Chemistry (1996) 39, 10. 
The subject disclosure also includes isotopically-labelled 
compounds, and the pharmaceutically acceptable salts 
thereof, which are identical to those recited in Formula I, but 
for the fact that one or more atoms are replaced by an atom 
having an atomic mass or mass number different from the 
atomic mass or mass number usually found in nature. 
Examples of isotopes that can be incorporated into com-
pounds of the present disclosure include isotopes of hydro-
gen, carbon, nitrogen, oxygen, phosphorous, fluorine and 
chlorine. Compounds of the present disclosure, prodrugs 
thereof, and pharmaceutically acceptable salts of said com-
pounds or of said prodrugs which contain the aforementioned 
isotopes and/or other isotopes of other atoms are within the 
scope of this disclosure. Certain isotopically-labelled com-
pounds of the present disclosure, for example those into 
which radioactive isotopes such as 3H and 14C are incorpo-
rated, are useful in drug and/or substrate tissue distribution 
assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes 
are particularly preferred for their ease of preparation and 
8 
detectability. Further, substitution with heavier isotopes such 
as deuterium, i.e., 2 H, can afford certain therapeutic advan-
tages resulting from greater metabolic stability, for example 
increased in vivo half-life or reduced dosage requirements 
and, hence, may be preferred in some circumstances. Isoto-
pically labelled compounds of Formula 1 of this disclosure 
and prodrugs thereof can generally be prepared by carrying 
out the procedures disclosed in the Schemes and/or in the 
Examples and Preparations below, by substituting a readily 
10 available isotopically labelled reagent for a non-isotopically 
labelled reagent. 
If a chiral center or another form of an isomeric center is 
present in a compound of the present disclosure, all forms of 
such isomer or isomers, including enantiomers and diastere-
15 omers, are intended to be covered herein. Inventive com-
pounds containing a chiral center may be used as a racemic 
mixture, an enantiomerically enriched mixture, or the race-
mic mixture may be separated using well-known techniques 
and an individual enantiomer may be used alone. An enantio-
20 merically enriched mixture means a mixture having greater 
than about 50% of a single enantiomer. In cases in which 
compounds have unsaturated carbon-carbon double bonds, 
both the cis (Z) and trans (E) isomers are within the scope of 
this disclosure. The compositions of the present disclosure 
25 can be substantially optically pure. Substantially optically 
pure means a composition having greater than 90%, prefer-
ably greater than 95%, most preferably greater than 98% of a 
single optical isomer. 
It must be noted that, as used in the specification and the 
30 appended claims, the singular forms "a," "an" and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "an aromatic com-
pound" includes mixtures of aromatic compounds, reference 
to "a pharmaceutical carrier" includes mixtures of two or 
35 more stitch carriers, and the like. 
In discussing the interactions of peptides with cysteine 
proteases, we have utilized the nomenclature of Schechter 
and Berger [Biochem. Biophys. Res. Commun. 27, 157-162 
(1967); incorporated herein by reference]. The individual 
40 
amino acid residues of a substrate or inhibitor are designated 
Pl, P2, etc. and the corresponding subsites of the enzyme are 
designated Sl, S2, etc. The scissile bond of the substrate is 
S 1-S 1'. The most important recognition sub sites of cysteine 
proteases are Sl and S2. 
45 
Amino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules; incorporated herein by refer-
ence]. An amino acid residue (AA) in a peptide or inhibitor 
structure refers to the part structure -NH--CHR1--CO-, 
50 
where R1 is the side chainofthe amino acid residue AA. It will 
be appreciated that at least one of the amino acid residues of 
the aza-peptide epoxides of the present disclosure may be 
substituted by one of the well known non-naturally occurring 
amino acid residues. Alterations such as these may serve to 
increase the stability, bioavailability and/or inhibitory action 
55 of the peptides of the present disclosure. Moreover, any of the 
aza-peptide epoxides described herein may, additionally, 
have a non-peptide macromolecular carrier group covalently 
attached to their amino and/or carboxy termini. Such macro-
molecular carrier groups may include, for example, lipid-
60 fatty acid conjugates, polyethylene glycol, or carbohydrates. 
The following figure shows the structure of an aza-peptide 
epoxide. An aza-amino acid residue is an alpha-amino acid 
residue where the alpha-carbon has been replaced by a nitro-
gen atom. It will be abbreviated as the three letter code for the 
65 amino acid preceded by an "A". Therefore, aza-alanine will 
be abbreviated as AAla and aza-aspartic acid as AAsp. The 
epoxide will be abbreviated as EP for the C2H2 0 residue. 




The term "C1 _10 alkylamino," as used herein, refers to a 
C1_10 alkyl group, as defined herein, to which is attached at 
least one amino substituent. 
The term "C3 _15 cycloalkyl" as applied herein is meant to 
include cyclic hydrocarbon chains. Examples of these cyclic 
hydrocarbon chains include cyclopropane, cyclobutane, 
cyclopentane, cyclohexane, cycloheptane, cyclooctane, 
cyclononane, cyclodecane, cycloundecane, etc. Aza-Arnino 
Acid Residue 
The complete structures of several aza-peptide epoxides 
and their abbreviated structures are shown in the following 
figure. 
The term "C2 _12 dialkylamino," as used herein, refers to 
10 two C1_10 alkyl groups, as defined herein, that are attached to 
an amino substituent. 
15 
The term "C1 _10 fluoroalkyl," as used herein, refers to a 
C1_10 alkyl group, as defined herein, to which is attached at 
least one fluorine substituent. 
The term "C1 _10 perfluoroalkyl," as used herein, refers to a 
cl-10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. 
The term "biotinyl," as used herein, refers to biotin without 
the biotin carboxyl hydroxyl group. 
The term "neurotoxin" as used herein, refers to a com-
pound that adversely affects cells of the nervous system. 
Suitable neurotoxins include compounds that induce axonal 
degeneration, for example by interfering with the neuronal 
cytoskeleton, in particularwithmicrotubles. Microtubule sta-
25 bilizers, for example Taxol® and Taccalonolides E and A, are 
preferred neurotoxins of the present disclosure. Taccalono-
lides E and A are described in Tinley TL et al. (2003) Tac-
calonolides E and A: Plant-derived steroids with microtu-
bule-stabilizing activity. Cancer Res. June 15;63(12):3211-
30 20, which is incorporated by reference in its entirety. 
Cbz-Leu-Glu-Thr-AAsp-EP-COOEt Colchicine, colcemid, nocadazol, vinblastine and vincristine 
are additional exemplary neurotoxins that affect microtubles. 
The term "Taxol®" is intended to be interchangeable with 
paclitaxel and refers to 5-beta,20-epoxy-1,2-alpha,4,7-beta, ~ ~H'Co (yVNH, coorn 
Ph/"---.0 N N,.... 
H H 0 
0 0 
Ph 
35 10-beta, 13-alpha-hexahydroxy-tax-11-en-9-one 4,10-diac-
etate 2-benzoate 13-esterwith (2R,3S)-N-benzoyl-3-phenyl-
isoserine; 7, l 1-Methano-5H-cyclodeca[3,4]benz[l ,2-b ]ox-
ete,benzenepropanoic acid derivative; Paclitaxel; TAX; 
Taxal; Taxol; Taxol A; substantially pure optical isomers, 
Cbz-Leu-Phe-AGln-EP-COOEt 40 racemates, prodrugs, and derivatives thereof. The structure of 
paclitaxel is provided below. 
The R3 group would be abbreviated as C02H, C02 Et, 
C02 R, CONHR, CONRR', or CO-AA-T ifthe aza-peptide 
epoxide has an epoxysuccinate moiety in its structure. Oth-
erwise, the structure of the R3 group would be drawn or 
45 
abbreviated. 
There are four structural isomers at the epoxide moiety, 
two trans isomers (2S,3S and 2R,3R) and two cis isomers 
(2R,3S and 2S,3R). The numbering of the carbons of the 
epoxide is shown above. The epoxide ring is also known as an 50 
oxirane ring. 
The term "amino," as used herein, refers to -NH2 or 
derivatives thereof formed by independent replacement of 
one or both hydrogen atoms thereon with a substituent or 
substituents independently selected from alkyl, alkanoyl, 55 
aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, het-
eroarylalkyl, and an amino protecting group. 
The term "C10 acyl," as used herein, refers to a C1 _10 alkyl 
group, as defined herein, having an attached carbonyl group. 
The term "C1_10 alkoxy," as used herein, refers to a C1 _10 
alkyl group, as defined herein, attached to the parent molecu- 60 
lar group through an oxygen atom. 
The term "C 10 alkyl" as used herein refers to a branched or 
unbranched hydrocarbon group of carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, 
and the like or branched or unbranched hydrocarbon groups 65 







The term "anti-hyperproliferative agent" as used herein, 
refers to a substance that reduces, inhibits or interferes with 
aberrant cell growth or division. Exemplary anti-hyperprolif-
erative agents include but are not limited to anti-cancer agents 
such as paclitaxel, chemotherapy agents, anti-sense poly-
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nucleotides, enzymatic polynucleotides, polypeptides, 
dideoxy nucleotides, chain terminating nucleotides, antibod-
ies, and small molecules. 
The term "hyperproliferative disorder" as used herein, 
refers to a pathology resulting from aberrant cell growth or 
division. 
The term "cal pain related pathology" as used herein, refers 
12 
to an abnormal cellular or systemic condition or symptom 
directly or indirectly caused, in part or in whole, by the 
activity of a cal pain protease. 
By the term "effective amount" of a compound as provided 
herein is meant a nontoxic but sufficient amount of the com-
pound to provide the desired utility. As will be pointed out 
below, the exact amount required will vary from subject to 
subject, depending on the species, age, and general condition 15 
of the subject, the severity of the condition or disease that is 
being treated, the particular compound used, its mode of 
administration, and the like. Thus, it is not possible to specify 
ing and/or inhibiting the condition/disease from occurring in 
an animal that may be at risk for or predisposed to the con-
dition/disease but does not yet experience or exhibit symp-
toms of the disease (prophylactic treatment), alleviation and/ 
or inhibition of symptoms of the condition/disease, 
diminishment of extent of condition/disease, stabilization 
(i.e., not worsening) of condition/disease, preventing/inhib-
iting spread of condition/disease, delaying or slowing of con-
dition/disease progression, amelioration or palliation of the 
10 condition/disease state, and combinations thereof. 
an exact "effective amount." However, an appropriate effec-
tive amount may be determined by one of ordinary skill in the 20 
art using only routine experimentation. 
The term "pharmaceutically acceptable salt(s)", as used 
herein, unless otherwise indicated, includes salts of acidic or 
basic groups which may be present in the compounds of 
Formula I. The compounds of Formula I that are basic in 25 
nature are capable of forming a wide variety of salts with 
various inorganic and organic acids. The acids that may be 
used to prepare pharmaceutically acceptable acid addition 
salts of such basic compounds of Formula I are those that 
form non-toxic acid addition salts, i.e., salts containing phar- 30 
macologically acceptable anions, such as the hydrochloride, 
hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phos-
phate, acid phosphate, isonicotinate, acetate, lactate, salicy-
late, citrate, acid citrate, tartrate, TFA, pantothenate, bitar-
trate, ascorbate, succinate, maleate, gentisinate, fumarate, 35 
gluconate, glucaronate, saccharate, formate, benzoate, 
glutamate, methanesulfonate, ethanesulfonate, benzene-
sulfonate, p-toluenesulfonate and pamoate [i.e., 1, 1 '-methyl-
ene-bis-(2-hydroxy-3-naphthoate )] salts. Those compounds 
of the Formula I that are acidic in nature, are capable of 40 
forming base salts with various pharmacologically accept-
able cations. Examples of such salts include the alkali metal 
or alkaline earth metal salts and particularly, the sodium and 
potassium salts. 
The term "pharmaceutically acceptable derivative" refers 45 
to any homolog, analog, or fragment corresponding to the 
aza-peptide epoxides of the present disclosure provided 
herein which inhibits protease activity and is relatively non-
toxic to the subject or host. 
The term "pharmaceutically acceptable" means a material 50 
that is not biologically or otherwise undesirable, i.e., the 
material may be administered to an individual along with the 
selected bicyclic compound without causing any undesirable 
biological effects or interacting in a deleterious manner with 
any of the other components of the pharmaceutical composi- 55 
tion in which it is contained. 
The following abbreviations have also been used: AFC, 
7-amino-4-trifluoromethylcoumarin; AAsp, aza-aspartic 
acid residue; AAsn, aza-asparagine; ALeu, aza-leucine; 
ALys, aza-lysine residue; AHph, aza-homophenylalanine 
residue; AOm, aza-omithine; AMC, 7-amino-4-methylcou-
marin; Cbz, Ph-CH20CO-; DCC, 1,3-dicyclohexylcarbo-
diimide; DMAP, 4-dimethylaminopyridine; DMF, N,N-dim-
ethylformamide; EDC, 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride; EtOAc, ethyl acetate; 
HOBt, 1-hydroxybenzotriazole; HRMS, high resolution 
mass spectrometry; IBCF, isobutyl chloroformate; NMM, 
4-methylmorpholine; Np2,2-naphthyl-alanyl; PhPr, Phenyl-
propyl; TFA, trifluoroacetic acid; THF, tetrahydrofuran; 
TLC, thin layer chromatography. 
One embodiment of the present disclosure provides aza-
peptide epoxides having the following structural Formula I: 
wherein, 
R1 is selected from the group consisting ofMv M2-AA1 , 
M2-AA2-AA1 , and M2-AA3 -AA2-AA1 ; 
M 1 is selected from the group consisting ofNH2--CO-, 
NH2--CS-, NH2-S02-, X-NH--CO-, X2N--CO-, 
X-NH-CS-, X2N--CS-, X-NH-S02-, X2N-
S02-, X--CO-, X-CS-, Y-S02-, Y-0---CO-, 
Y---0-CS-, phenyl substituted with K, phenyl disubsti-
tuted with K, and morpholine-CO-; 
M2 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, X2N-
CO-, X-NH-CS-, X2N--CS-, X-NH-S02-, 
X2N-S02-, X--CO-, X--CS-, Y-S02-, Y-0-
CO-, Y ---0-CS-, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, and morpholine-CO-; 
X is selected from the group consisting of H, C1 _10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, phenyl disub-
stituted with K, phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K, naph-
thyl trisubstituted with K, C1_10 fluoroalkyl with an attached 
phenyl group, cl-10 alkyl with an attached phenyl group, 
As used herein, and without limitation, the term "deriva-
tive" is used to refer to any compound which has a structure 
derived from the structure of the compounds of the present 
disclosure and whose structure is sufficiently similar to those 
disclosed herein and based upon that similarity, would be 
expected, by one skilled in the art, to exhibit the same or 
similar activities and utilities as the claimed compounds. 
As used herein, "treat'', "treating", and "treatment" are an 
approach for obtaining beneficial or desired clinical results. 
For purposes of embodiments of this disclosure, beneficial or 
desired clinical results include, but are not limited to, prevent-
60 cl-10 alkyl with two attached phenyl groups, cl-10 alkyl with 
an attached phenyl group substituted with K, C1 _10 alkyl with 
two attached phenyl groups substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1 _10 alkyl with an attached 
naphthyl group substituted with K, C1 _10 alkyl with an 
65 attached phenoxy group, biotinyl, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phenoxy 
group; 
US 8,013,014 B2 
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Y is selected from the group consisting ofC1_10 alkyl, C3_1s 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted with 
J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluore-
nyl, phenyl, phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naphthyl sub- 5 
stituted with K, naphthyl disubstituted with K, naphthyl 
trisubstituted with K, C1_10 fluoroalkyl with an attached phe-
nyl group, cl-10 alkyl with an attached phenyl group, cl-10 
alkyl with two attached phenyl groups, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl with 
10 
two attached phenyl groups substituted with K, C1_10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an attached 
naphthyl group substituted with K, C1_10 alkyl with an 
attached phenoxy group, biotinyl, and C1_10 alkyl with an 15 
attached phenoxy group substituted with K on the phenoxy 
group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl-0-CO- 20 
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C10 
alkyl, C10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 25 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, glycine, 30 
serine, threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, alpha-ami-
nobutanoic acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indoline 35 
2-carboxylic acid, 2-azetidinecarboxylic acid, pipecolinic 
acid (2-piperidine carboxylic acid), 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzylcys-
teine, NH2-CH(CH2CHEt2)--C02H, alpha-aminohep-
tanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, NH2--CH 40 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2-cyclohexyl)-
C02H, NH2--CH(CH2-cyclopentyl)-C02H, NH2--CH 
(CH2-cyclobutyl)-C02H, NH2--CH(CH2-cyclopropyl)-
C02H, trifluoroleucine, 4-fluorophenylalanine, lysine 
substituted on the epsilon nitrogen with a biotinyl group, and 45 
hexafluoroleucine; 
R2 is selected from the group consisting of C1_10 alkyl, 
cl-10 alkyl substituted with Q, cl-10 alkyl substituted with 
phenyl, C1_10 alkyl with an attached phenyl substituted with 
14 
NH2), isothiureido (-S-C(=NH)NH2), amino, C1_6 alky-
lamino, c2-12 dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , CONR6R7 , CO-AA4 -T, 
0 0 ANI 
~o, AO 
0 0 
Ace Aco f ,, 
I:, ~ 
0 0 
A8~" AB ~ , 
I# ~ 
~ 
Rs is selected independently from the group consisting of 
cl-10 alkyl, c3-1S cyclized alkyl, cl-10 alkyl with a phenyl 
group attached to the cl-10 alkyl, c3-1S cyclized alkyl with an 
attached phenyl group, C1_10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with an attached phenyl 
group disubstituted with K, C1_10 alkyl with an attached phe-
nyl group trisubstituted with K, C3_1s cyclized alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl with a 
naphthyl group attached to the cl-10 alkyl, c3-1S cyclized 
alkyl with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl with 
an attached naphthyl group disubstituted with K, C1_10 alkyl 
with an attached naphthyl group trisubstituted with K, and 
C3_1s cyclized alkyl with an attached naphthyl group substi-
tuted with K; 
T is selected independently from the group consisting of 
OH, OR8 , NHR9 , and NR8R9 ; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2--CH 
K, C1_10 alkyl substituted with naphthyl, C1_10 alkyl with an 50 
attached naphthyl substituted with K, phenyl, phenyl substi-
tuted with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl substituted with CONH2, C1_10 alkyl substituted with 
CONHR4 , C1_10 alkyl substituted with C02H, C1_10 alkyl 
substituted with C02R4 , CH2CH2SCH3, CH2-3-indolyl, 55 
CH2-2-thienyl, CH2-2-furyl, CH2-3-furyl, CH2-2-imidazyl, 
C1_10 alkyl substituted with G, C1_10 alkyl with an attached 
phenyl substituted with G, C1_10 alkyl with an attached naph-
thyl substituted with G, phenyl substituted with G, and naph-
thyl substituted with G; 60 (CH2CHEt2)-C02H, alpha-aminoheptanoic acid, NH2-
CH(CH2-l-naphthyl)-C02H, NH2-CH(CH2-2-naphthyl)-
C02H, NH2--CH(CH2-cyclohexyl)-C02H, NH2--CH 
(CH2-cyclopentyl)-C02H, NH2--CH(CH2-cyclobutyl)-
C02H, NH2--CH(CH2-cyclopropyl)-C02H, 
R4 is selected from the group consisting of C1_10 alkyl and 
cl-10 alkyl substituted with phenyl; 
Q is selected independently from the group consisting of 
C1_10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy substituted with 
phenyl, and C1_10 alkyl-S- substituted with phenyl; 
G is selected independently from the group consisting of 
amidino (-C( NH)NH2), guanidino (-NHC(=NH) 
65 trifluoroleucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, and hexafluoro-
leucine; 
US 8,013,014 B2 
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R6 and R7 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, C3 _20 cyclized alkyl, C1_10 alkyl with 
16 
a phenyl group attached to the cl-10 alkyl, cl-10 alkyl with 
two phenyl groups attached to the cl-10 alkyl, c3-20 cyclized 
alkyl with an attached phenyl group, phenyl, phenyl substi- 5 
tuted with K, C1 _10 alkyl with an attached phenyl group sub-
stituted with K, C1 _10 alkyl with an attached phenyl group 
disubstituted with K, C1_10 alkyl with an attached phenyl 
group trisubstituted with K, C1_10 alkyl with two phenyl 
groups attached to the C1 _10 alkyl and substituted with Kon 10 












to the C1 _10 alkyl and disubstituted with K on the phenyl 
groups, C3 _20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [-N 
(CH2CH2 )0] ring attached through nitrogen to the alkyl, 15 
C1 _10 alkyl with a piperidine ring attached through nitrogen to 
the alkyl, C1 _10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl, C1 _20 alkyl with an OH group attached to 
the alkyl, --CH2 CH2CH2 0CH3 , C1_10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl group, 20 











an attached cyclohexyl group, -NH-CH2CH2 -( 4-hydrox-
yphenyl), -NH--CH2 CH2 -(3-indolyl), C1 _10 alkyl with an 
attached 2-furyl group, C1 _10 alkyl with an attached 3-furyl 
group, and C1_5 alkyl with an attached phenyl and a hydroxyl 25 






R8 and R9 are selected independently from the group con-
sisting of H, C 1 _10 alkyl, pheny 1, nitropheny 1, and C 1- 0 alky 1 
substituted with phenyl; 
the stereochemistry at the epoxide carbons 2 and 3 is 30 








PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH2 CH2CH2 CH3 ) 2 , 
PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH2 Ph)2 , 
The following compounds are representative of the present 
disclosure: 
APhe-(trans )-EP-COOEt, 
Cbz-APhe-( trans)-EP-COO Et, 





Boe-Nle-AHph-( trans )-EP-COO Et, 
Boe-Nle-AHph-( trans )-EP-CH2 CH2 Ph, 
Boc-Nva-AHph-(trans )-EP-CH2CH2 Ph, 
Boc-Abu-AHph-(trans)-EP-CH2 CH2Ph, 
Boc-Ala-AHph-(trans)-EP-CH2 CH2 Ph, 





















35 Cbz-Leu-Glu-Thr-AAsp-(2S,3S)-EP-CON(CH2Ph)2 , 
Cbz-Ile-Glu-Thr-AAsp-(2S,3 S )-EP-CON ( CH2 Ph )2 , 
Cbz-Leu-Glu-Thr-AAsp-(2S,3S )-EP-CON ( CH3)CH2Ph, 
PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH3 )CH2 Ph, 
Cbz-Ile-Glu-Thr-AAsp-(2S,3 S )-EP-CON ( CH3 )CH2 Ph, 








PhPr-Val-Ala-AAsp-(S,S)-EP-COOCH2 CH2 Ph, 
PhPr-Val-Ala-AAsp-(S,S)-EP-CONHCH2 CH3 , 
50 PhPr-Val-Ala-AAsp-(S,S)-EP-CONHCH2 Ph, 
PhPr-Val-Ala-AAsp-(R,R)-EP-CONHCH2Ph, 













65 Cbz-Asp-Glu-Val-AAsp-(S,S)-EP-CO-Phe-NH2 , 
Cbz-Asp-Glu-Val-AAsp-(S,S)-EP-CONHCH2Ph, 
Cbz-Asp-Glu-Val-AAsp-(S,S)-EP-COOCH2Ph, 




Cbz-Ile-Glu-Thr-AAsp-(S,S )-EP-CO-Ala-NHCH2 Ph, 
H02CI 0 
Cbz-Asp-Glu-Val'-... _.,.NypA co 





Ho2cl 0 el 
Cbz-Asp-Glu-Val'-... _.,.N~ ~ 







Cbz-Asp-Glu-Val'-... _.,.NypA u 
N N ' 
H 0 oC( l;j 
I N ..-::; 
H02CI 0 
Cbz-Asp-Glu-Val'-... _.,.NypA u 
N N ' 
Ho~ l;j 




Cbz-Asp-Glu-Val'-... _.,.NypA u 
N N ' 





Cbz-Ile-Glu-Thr-AAsp-(S,S )-EP-COOCH2 Ph, 
Cbz-Ile-Glu-Thr-AAsp-(R,R )-EP-COOCH2 Ph, 
Cbz-Ile-Glu-Thr-AAsp-(R,R )-EP-CONGCH2 Ph. 
35 
EXEMPLARY METHODS OF PREPARATION 
H02CI 0 40 
Cbz-Asp-Glu-Val'-... _.,.N~ c9/J A. Preparation of the Epoxide Portion A variety of epoxides can be synthesized by following the 
schemes shown below. Any aldehyde can be reacted with 
malonic acid to form the a,~-unsaturated acid, which can be 




Cbz-Asp-Glu-Val'-... _.,.N~ 0 
N N , 
H 0 
0 
45 further transformed into an ethyl ester. The double bond is 
epoxidized using t-butyl peroxide and t-butyl lithium, fol-
lowed by the de blocking of the ethyl ester to yield the substi-
tuted epoxide. This epoxide can then be coupled to the respec-
tive substituted hydrazide to yield an aza-peptide epoxide 
50 using peptide coupling procedures. 
The diethyl ester epoxysuccinate can also be deblocked to 
yield the diacid, which can be selectively coupled to different 
alcohols to yield a variety of epoxide monoesters. Hydrolysis 
of diethyl epoxysuccinate also yields the monoethyl ester, 
55 which can be coupled with a variety of mono substituted and 
disubstituted amines to form amide derivatives of ethyl 
epoxysuccinate. The ethyl ester can then be hydrolyzed to the 
acid. These epoxides can then be coupled to substituted 
hydrazides to yield aza-peptide epoxides. These processes are 



































































B. Preparation of the Peptide Portion 
The peptide portion of the aza-peptide epoxide inhibitor 
can be prepared using standard peptide chemistry which is 
well described in publications such as The Peptides, Analysis, 
Synthesis, Biology, Vol. 1-9, published in 1979-1987 by Aca-
demic Press; Houben-Wey! Methoden der Organischen Che-
mie, Vol. 15, Parts 1and2, Synthese von Peptiden, published 
20 
M 1 group could be introduced by reaction with an amino acid 




The techniques for introduction of the M1 group are well 
10 documented in The Peptides, Houben-Weyel, and many other 
textbooks on organic synthesis. For example reaction with 
cyanate orp-nitrophenyl cyanate would introduce a carbamyl 
group (M1=NH2CO-). Reaction with Me2NCOCI would 
introduce the Me2NCO- group. Reaction with p-nitrophe-
nyl thiocarbamate would introduce a thio carbamyl group 
(M1=NH2CS-). Reaction with NH2 S02Cl would introduce 
the NH2 S02- group. Reaction with Me2NS02 Cl would 
15 
20 
introduce the Me2NS02-group. Reaction with a substituted 
alkyl or aryl isocyanate would introduce the X-NH-CO-
group where Xis a substituted alkyl or aryl group. Reaction 
with a substituted alkyl or aryl isothiocyanate would intro-
duce the X-NH--CS- group where Xis a substituted alkyl 
or aryl group. Reaction with X-S02-Cl would introduce 
the X-S02 - group. Reaction with a substituted alkyl or 
aryl acid chloride would introduce an acyl group (M=X-
CO-). For example, reaction with Me0-CO-CH2CH2 -
30 CO--Cl would give the X--CO- group where X is a C2 
alkyl substituted with a C1 alkyl-OCO- group. Reaction 
with a substituted alkyl or aryl thioacid chloride would intro-
duce a thioacyl group (M=X--CS-). Reaction with a sub-
35 
stituted alkyl or aryl sulfonyl chloride would introduce the 
X-S02-group. For example, reaction with dansyl chloride 
would give the X-S02- derivative where X was a naphthyl 
group mono substituted with a dimethylamino group. Reac-
tion with a substituted alkyl or aryl chloroformate would 
40 introduce the X---0-CO- group. Reaction with a substi-
tuted alkyl or aryl chlorothioformate would introduce the 
X---0-CS-. There are many alternate reaction schemes 
which could be used to introduce all of the above M1 groups 
45 to give either M1-AA-OH or M1 -AA-OR'. 
The M1 -AA-OH derivatives could then be used directly in 
the preparation of peptide hydrazides or could be converted 
into the dipeptides, tripeptides, and tetrapeptides M1 -AA-
AA-OH, M1 -AA-AA-AA-OH, or M1 -AA-AA-AA-AA-OH 
50 which could then be converted to peptide hydrazides. The 
substituted peptides M1 -AA-AA-OH, M1 -AA-AA-AA-OH, 
or M1 -AA-AA-AA-AA-OH could also be prepared directly 
from H-AA-AA-OH, H-AA-AA-AA-OH, or H-AA-AA-
AA-AA-OH using the reactions described above for intro-
55 duction of the M1 group. Alternatively, the M1 group could be 
introduced by reaction with carboxyl blocked peptides to give 
M1 -AA-AA-OR', M1-AA-AA-AA-OR', or M1-AA-AA-AA-
AA-OR', followed by the removal of the blocking group R'. 
by Georg Thieme Verlag, Stuttgart in 1974; and Houben- 60 
Wey! Methods of Organic Chemistry, Vol. E22, Parts a, b, c, 
and d, Synthesis of Peptides and Peptidomimetics published 
C. Peparation of Peptide Hydrazides 
Usually, peptide hydrazides are synthesized by reaction of 
an amino acid or peptide ester with hydrazine or by direct 
coupling of an amino acid or peptide acid with hydrazine as 
shown in the following two figures. They can also be synthe-
sized directly by reaction of an amino acid or peptide ester 
with hydrazine. 
by Georg Thieme Verlag, Stuttgart 2000-2003 (references 
incorporated herein by reference). 
The M1 group can be introduced using a number of differ- 65 
ent reaction schemes. First, it could be introduced directly on 
an amino acid as shown in the following scheme (top), or the 




Cbz-~~ 1. SOCl2/CH30H 
; OH 2. NH2- NH2/CH30H 
R.2 
2. NaBJLi or NaCNBH3 10 
The side chain of the aza-amino acid residue can be intro-
duced by reductive amination as shown specifically in the 
previous figure or by other methods known by those skilled in 

















The precursors for basic side chain aza-peptide epoxides 
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D. Preparation of the Aza-Peptide Epoxide -continued 
0 
1. EDC/HOBt Coupling Method 
The epoxide portion of the aza-peptide epoxide is coupled 5 
to the substituted hydrazide by reacting the epoxide portion, 
the substituted hydrazide, EDC, and HOBt in DMF to form 








EDC, HOBt, DMF 15 
Methods for the protection and deprotection and replacement 
aX ~OEt; b X~NH2; 
cX ~Ot-Bu; dX~ OH 
6Y~COOEt 
7Y~COOBzl 
8 Y ~ CH2CH2Ph 
of an amino protecting group with another moiety are well 25 
known. Deprotection of other side chain protecting groups 
were carried out by standard methods. 
Reagents: (i) BrCH2COOEt, NMM, DMF; NH3/MeOH, 
0.1 eq NaCN, DMF. (ii) BrCH2 COO-tBu, NMM DMF. (iii) 3, 
EDC, HOBt, DMF orNMM, IBCF, DMF. (iv) TFA (can be 
used to deblock the t-Butyl Group in certain peptides where 
X=O-tBu). 2. The Mixed Anhydride Method 
Another coupling method is the mixed anhydride method. 30 
In this method, the epoxide portionofthe aza-peptide epoxide 
Examples of the preceding methods are exhibited below 
(additional examples are described in U.S. patent application 
Ser. No. 10/603,054, which is incorporated herein by refer-
ence in its entirety): 
is coupled to the substituted hydrazide by reacting the 
epoxide portion (carboxylic acid) with NMM in DMF and 
IBCF followed by the substituted hydrazide to form the aza-
peptide epoxide (see the following figure). Methods for the 35 
protection and deprotection of side chain protecting groups 
are well known. 
E. Synthetic Procedures and Examples 
1. Material and Methods. Mono and dipeptidyl methyl 
esters were purchased from Bachem Bioscience Inc., King of 
Prussia, Pa. Tripeptides were synthesized using standard cou-
NMM, IBCF, DMF 
The following figure shows how these methods are used to 
build the AAsp and AAsn derivatives. 
R~peptidyl 
i or ii -
40 piing procedures such as the mixed anhydride method. The 
1H NMR spectra were obtained using a Varian Mercury 300 
MHz spectrometer. Electrospray ionization (ESI), fast-atom-
bombardment (FAB) and high-resolution mass spectrometry 
were performed using Micromass Quattro LC and VG Ana-
45 lytical 70-SE instruments. Elemental analysis was performed 
by Atlantic Microlab Inc., Norcross, Ga. 
2. Preparation of Peptidyl Hydrazides (3). Anhydrous 
hydrazine (10 eq) was added to a solution of the peptidyl 
methyl ester (1 eq) in MeOH at room temperature, and the 
50 resulting mixture was then stirred for 16 hours. As with most 
hydrazides, excess hydrazine and solvent were removed by 
evaporation. The resulting residue was washed with ethanol 
and ether to give the desired peptidyl hydrazide (3) as a white 
solid. MS and 1 H NMR (CDCl3 or DMSO-d6 ) were consis-
55 tent with the proposed structures. 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NH-NH2 was purified 
by chromatography on a silica gel colunm using 1 :9 MeOH: 
CH2Cl2 as the eluent; white solid, yield 56%. 
Cbz-Glu(O-tBu)-Val-NH-NH2 was purified by chroma-
60 tography on a silica gel colunm using 1 :9 MeOH:CH2 Cl2 as 
the eluent; white solid, yield 47-53%. 
Cbz-Ile-Glu(O-tBu)-Thr-NH-NH2 , white solid, yield 
91%. 
3. Preparation of Peptidyl-AA2 -NH-NH--CH2C00-
65 tBu ( 4c ). Neat t-butyl bromoacetate (1 eq) was added to a 
stirred solution of the peptide hydrazide (3) and NMM (1 eq) 
in DMF pre-cooled at -10° C. The resulting solution was 
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stirred for 30 min at -10° C., after which the mixture was 
allowed to react at room temperature for 20 hours. The DMF 
was removed by evaporation, and the resulting residue was 
washed with water, filtered, and dried in vacuo. Purification 
on a silica gel column using the appropriate solvent gave 4c 5 
(yields=48-6S%). MS and 1H NMR (DMSO-d6 or CDC13 ) 
were consistent with the proposed structure. 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NH-NH-CH2COO-
tBu was purified by column chromatography on silica gel 
using 2:18:S MeOH:CH2Cl2 :EtOAc as the eluent; white 10 
solid, yield 6S%. MS (ESI) m/z 736.6 [(M+ltJ. 1H NMR 
(DMSO-d6): 0.90 (d, 6H, Val), 1.49 (s, 27H, tBu), 1.8S-2.20 
(m, 3H, Val and Glu), 2.21 (m, 2H, Glu), 2.40-2.70 (m, 2H, 
Asp CH2 ), 3.30 and 3.38 (m, 3H, NHCH2 and NHCH2 ), 
4.0S-4.30 (m, 3H, a-H), S.OS (m, 2H, Cbz), 7.20-7.40 (m, SH, 15 
Ph), 7.60-7.9S (m, 3H, NH), 9.2 (m, lH, NH). 
Cbz-Glu(O-tBu)-Val-NH-NH-CH2COO-tBu was puri-
fied by column chromatography on silica gel using 2: 18:S 
MeOH:CH2 Cl2 :EtOAc as the eluent; white solid, yield 78%. 
MS (ESI)m/z S6S.3 [(M+ltJ. 1HNMR(CDC13 ): 0.9S (t, 6H, 20 
Val), 1.49 (s, 18H, tBu), 1.8S-2.20 (m, 3H, Val and Glu), 2.21 
(m, 2H, Glu), 3.4S-3.70 (m, 3H, NHCH2 and NHCH2 ), 4.2S-
4.30 (m, 2H, a-H), S.OS (m, 2H, Cbz), S.8S (d, lH, NH), 7.0S 
(d, lH, NH), 7.20-7.40 (m, SH, Ph), 8.00 (m, lH, NH). 
26 
solution, 6S mL, 1.1 eq). The mixture was stirred at - 78° C. 
for S min, then a solution of diethyl fumarate (17.2 g, 0.1 M, 
1 eq) in THF (SO mL) was added. The reaction mixture was 
stirred at room temperature for 2 hours (monitored by TLC). 
Sodium sulfite (10 g) was added and the mixture was stirred 
for 20 min. The mixture was concentrated to ca. 100 mL, 
diluted with ether (100 mL), filtered through yiatomaceous 
earth ( celite ), and evaporated. To the residue was added 1 M 
HCl (100 mL). The product trans-oxirane-2,3-dicarboxylic 
acid diethy 1 ester was extracted with EtOAc (3x100 mL ), and 
the organic layer was washed with saturated NaCl (3xSO mL ), 
dried over MgS04 , and the solvent evaporated. Chromatog-
raphy on a silica gel column with 2:3 EtOAc:hexane afforded 
the product trans-oxirane-2,3-dicarboxylic acid diethyl ester 
(yield=S2%). 
6. Preparation of trans-Oxirane-2,3-dicarboxylic Acid. A 
solution of 1 M NaOH (98 mL, 1.9 eq) was added to trans-
oxirane-2,3-dicarboxylic acid diethyl ester (9.8 g, S2 mM) in 
MeOH (30 mL) at 0° C. The resulting solution was stirred for 
1 hat 0° C., then for 30 min at room temperature, after which 
the solution was acidified to pH 3. Water and MeOH were 
evaporated. The residue was treated with EtOH (ISO mL), 
filtered and the solvent evaporated, to give trans-oxirane-2,3-
dicarboxylic acid as a colorless semisolid (yield=97%). 
7. Preparation of trans-Oxirane-2,3-dicarboxylic Acid 
Monobenzyl Ester (S, Y=COOBzl). The reagent EDC (2.32 
g, 11 mM) was added to a stirred solution of trans-oxirane-
2,3-dicarboxylic acid (1.32 g, 10 mM), benzyl alcohol (1.08 
g, 10 mM), and DMAP (122 mg, 1 mM) in DMF (100 mL), 
which has been cooled to 0° C. The resulting solution was 
stirred for IS hat room temperature. After removal ofDMF, 
the residue was purified by chromatography on two succes-
sive columns using 1:9 MeOH:CH2 Cl2 as the eluent, fol-
lowed by column chromatography using 1:4 MeOH:CH2Cl2 
Cbz-Leu-Glu(O-tBu)-Thr-NH-NH-CH2COO-tBu was 25 
purified by column chromatography on silica gel using 1:9 
MeOH:CH2 Cl2 as the eluent; white solid, yield 34%. MS 
(ESI) m/z 680 [(M+lt]. 1H NMR (DMSO-d6): 0.7-0.9 (t, 
6H, Leu CH3 ), 1.0 ( d, 3H, Thr CH3 ), 1-1.3 (m, 2H, Leu CH2 ), 
1.3-1.S (m, 18H, tBu), 1.S-1.8 (m, 2H, Leu CH andG!u CH2 ), 30 
1.8-1.9S (m, lH, Glu CH2 ), 2.1-2.3 (m, 2H, Glu CH2 ), 3.4 (d, 
2H, NCH2 ), 3.9 (m, lH, a-H), 4.1 (m, lH, a-H and Thr 
CH-OH), 4.3 (m, lH, a-H), 4.9 (d, lH, NH), S.03 (m, 2H, 
Cbz), 7.3-7.4 (m, SH, phenyl), 7.S (d, lH, NH), 7.6 (d, lH, 
NH), 8.0S (d, lH, NH), 9.2 (d, lH, NH). 
Cbz-Ile-Glu(O-tBu)-Thr-NH-NH-CH2COO-tBu was 
purified by column chromatography on silica gel using 1:9 
MeOH:CH2 Cl2 as the eluent; white solid, yield 26%. MS 
(ESI) m/z 680 [(M+ltJ. 1H NMR (DMSO-d6): 0.7-0.9 (t, 
6H, Ile CH3 ), 0.9-1.0 (d, 3H, Thr CH3 ), 1-1.2 (m, 2H, Ile 40 
CH2 ), 1.3-1.S (s, 18H, tBu), 1.6-1.8 (m, 2H, Ile CH and Glu 
CH2 ), 1.8-1.9 (m, lH, Glu CH2 ), 2.1-2.3 (m, 2H, Glu CH2 ), 
3.4 (d, 2H, NCH2 ), 3.9 (m, 2H, a-H), 4.1 (m, lH, a-H), 4.3S 
(m, lH, Thr CH-OH), 4.8 (d, lH, NH), S.03 (s, 2H, Cbz), 
S.OS (d, lH, NH), 7.3-7.4 (m, SH, phenyl), 7.7 (d, lH, NH), 45 
8.0S (d, lH, NH), 9.2 (s, lH, NH). 
35 as the eluent to give S (Y=COOBzl), as a dark yellow oil 
(yield=66%). 1H NMR: 3.60 (d, lH, epoxy), 3.7S (d, lH, 
epoxy), S.18 (s, 2H, PhCH2 0), 7.38 (d, SH, Ph). 
4. Preparation of (2S,3S) and (2R,3R)-Oxirane-2,3-dicar-
boxylic Acid Monoethyl Esters (or Monoethyl Epoxysucci-
nates, S, Y=COOEt). Enantiomerically pure diethyl 
epoxysuccinate esters (2S,3S) and (2R,3R) were synthesized 50 
from diethyl D-(-) and L-( + )-tartrate, respectively, following 
the general method developed by Mori and Iwasawa. This 
procedure involved three steps including bromination, elimi-
nation, and cyclizations. The selective hydrolysis of one ester 
to yield monoethyl epoxysuccinates was performed by a 55 
method similar to that described previously by Rich and 
Schaschke. 
S. Preparation of trans-Oxirane-2,3-dicarboxylic Acid 
Diethyl Ester (or Diethyl Epoxysuccinate). The trans-ox-
irane-2,3-dicarboxylic acid diethyl ester was synthesized 60 
using a general procedure for the stereocontrolled epoxida-
tion of a,~-unsaturated carbonyl compounds, which was 
similar to the method previously described by Meth-Cohn. 
An anhydrous solution oft-butyl hydroperoxide in toluene 
(3.3 M solution, 46 mL, l .Seq), was added to freshly distilled 65 
THF (240 mL) at -78° C. under argon. This was followed by 
the addition of a solution of butyl lithium in pentane (1.7 M 
8. General Procedure for Coupling Oxirane Dicarboxylic 
Acid Monoethyl Esters to Amines. The procedure used to 
synthesize amide derivatives of epoxysuccinate monoethyl 
esters was similar to that of Therrien et al (Biochemistry 2001 
40 p 2702). To a solution of epoxysuccinate monoethyl ester 
(1 g, 6.2S mM), amine/amino acid (1.2 eq) and HOBt (1 eq) 
in CHC13 (30 mL) at 0° C. was added EDC (1.1 eq) slowly in 
S portions. The reaction was stirred for one hour at 0° C. and 
then subsequently at room temperature for 16 hours. The 
solvent was evaporated and the residue was partitioned 
between EtOAc (SO mL) and dH20 (S mL ). The organic layer 
was washed with O.S M HCl (2x10 mL), sat NaHC03 (2xSO 
mL), dried over MgS04 and concentrated. In general, the 
oxirane-2,3-dicarboxylic acid monoamides were obtained in 
43-74% yield. The crude product was purified by chromatog-
raphy on a silica gel column using 1: 1 EtOAc:hexanes as the 
eluent to yield a white solid. Hydrolysis of the ester by KOH 
(1.2 eq) gave the desired amides (yields=6S-9S% ). 
9. (2S,3S)-Oxirane-2,3-dicarboxylic Acid Monobenzyl 
Ester (HOOC-EP-COOCH2 Ph). 
1H NMR (CDC13 ): 3.70 (d, 
2H, epoxy), S.22 (d, 2H, CH2 Ph), 7.3S (m, SH, Ph). 
10. (2R,3R)-Oxirane-2,3-dicarboxylic Acid Monobenzyl 
Ester (HOOC-EP-COOCH2 Ph). 
1H NMR (CDC13 ): 3.6S (d, 
2H, epoxy), S.17 (d, 2H, CH2 Ph), 7.32 (m, SH, Ph). 
Utility of the Compounds of the Present Disclosure 
Peptide aza-peptide epoxides are irreversible inhibitors for 
cysteine proteases. Peptide aza-peptide epoxides containing 
hydrophobic aza-amino acid residues in the Pl and/or P2 site 
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have been found to be excellent inhibitors of cysteine pro-
teases including cathepsin B and papain. We show that pep-
tide aza-peptide epoxides containing aza-amino acid residues 
with anionic side chains in the Pl site are excellent inhibitors 
of caspases. Legumain is inhibited by aza-peptide expoxides 
with a Pl aza-asparagine residue. Clostripain and gingipain 
are inhibited by aza-peptide epoxides with Pl basic side 
chains. Peptide aza-peptide epoxides containing aza-amino 
acid residues with hydrophobic side chains at the P2 site have 
also been found to be excellent inhibitors of several cysteine 
proteases including papain, cathepsin B, calpain I, and 
calpain II. These structures may be used in vivo to treat 
diseases such as cancer and neurodegenerative diseases 
which result from the uncontrolled proteolysis by cathepsin 
described by Stennicke and Salvesen. Assays using the fluo-
rogenic substrate Z-DEVD-AFC O'-ex =400 nm, "-em =505 nm) 
were carried out on a Molecular Devices fNax fluorescence 
microplate reader. Inhibition rates and equilibria were deter-
mined by the progress curve method. The standard 100 µL 
reaction was started by adding enzyme to a mixture of sub-
strate (final concentration of Z-DEVD-AFC 100 µM) and 
various amounts of inhibitor in buffer (50 mM Hepes, 100 
mM NaCl, 0.1 % (w/v) CHAPS, sucrose 10% (w/v), and 10 
10 mM DTT, at pH 7.4 ). The caspases were pre-activated for 10 
min at 37° C. in the presence of 10 mM DTT. 
2. Structure-Activity Relationships 
Table I shows the inhibition rate constants (k06)[I]) for the 
15 
inhibition of papain, cathepsin B, and cal pain by aza-peptide 
epoxides. The inhibition constants are second-order rate con-
stants and the inhibitors with the higher numbers are more 
potent. 
B, calpain, caspases, and related cysteine proteases. These 
inhibitors may be used in vitro to prevent proteolysis which 
occurs in the process of production, isolation, purification, 
storage, or transport of peptides and proteins. These inhibi-
tors may be useful as therapeutic agents for treatment of 
neurodegeneration, viral infections, muscular dystrophy, 20 
myocardial tissue damage, tumor metastasis, and bone 
resorption. 
TABLE I 
Inhibition of Papain, Cathepsin B, and 
Cal pain by Aza-peptide Epoxides. 
1. Enzyme Assays. 
Caspase-1. The preparation of the autolytically stable 
caspase-1 variant used in these studies has been described 
previously. Briefly, the variant contains a mutation (D381E) 
which renders it resistant to autolytic inactivation, but has no 
detectable affect on enzyme activity as compared to the natu-
rally occurring enzyme. The enzyme variant was expressed in 
25 Inhibitor 
E. coli, purified first by immobilized metal chromatography 30 
via the N-terminal N-His tag, treated with excess oxidized 
glutathione to stabilize the reactive thiolate, and then re-
















Cbz-Phe-APhe-trans-EP-CH 2CH 2Ph 
40 ~~~:~:~:~~~:~:::~~:~~~~t 
Inhibition data was measured using the progress curve 
assay method. Serial dilutions of each compound were pre- 35 
pared using an initial 8-fold dilution of a DMSO stock into 
HGE (100 mM HEPES, 20% glycerol v/v, 0.5 mM EDTA), 
followed by seven serial two-fold dilutions into HGE and 
12.5% DMSO, thus maintaining constant DMSO through the 
dilution series. Ten µL of diluted stocks or of vehicle (HGE 
and 12.5% DMSO) were placed in triplicate onto a 96-well 
microtiter plate, allowing several compounds to be tested on 
each plate. The plate was covered to minimize evaporation, 
and the plate was pre-warmed to 30° C. for 20 minutes. 
Enzyme was diluted into 10.0 mL of assay buffer (HGE, 5 45 
mM DTT, plus 15 µMAc-YVAD-AMC, 2 nM approximate 
final enzyme concentration), and this activated reaction mix-
ture was added to the plate at 90 µL/well. Progress of substrate 
hydrolysis was monitored for 900 s in a LabSystems 
(Needham, Mass.) Fluoroskan Ascent fluorescent plate-
reader using 385 and 460 nm excitation and emission filters, 
respectively, and a photomultiplier gain setting of 10. Tripli-
cate curves were averaged and fit by nonlinear regression to 
the equation for irreversible inactivation shown below. 
where F 0 was routinely fixed to zero, since fluorescence val-
ues were always adjusted to an origin ofO. The second order 
rate constant k
0
n (M- 1s- 1) was obtained from the slopes by 
linear regression, and errors represent the standard deviation 
of the regression slope. 
Caspase-3, -6, and-8. Caspase-3, -6 and-8 were expressed 
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TABLE I-continued 
Inhibition of Papain, Catbepsin B, and 




















NI =no inhibition, 
EP = epoxide, 
PhPr = PhCH,cH,CO-. 










The aza-peptide epoxide inhibitors are quite specific and 
do not react with serine proteases. Table II shows tests of a 
number of aza-peptide epoxide inhibitors with chymotrypsin. 


































NI= no inhibition, 
EP = epoxide. 
Table III shows the rate of inhibition of dipeptidyl pepti-
dase I (DPPI, cathepsin C) by aza-peptide epoxides. 
TABLE III 







EP = epoxide. 
k
0







Tables IV and V show the rates of inhibition of caspases by 
aza-peptide epoxides. Several of the inhibitors are highly 
35 effective with inhibition rate constants in the range of300,000 
to over 1 million M- 1s-1 . They also exhibit a high degree of 
selectivity for the target enzyme. They don't inhibit aspartyl 
protease, serine proteases such as granzyme B, which is also 
specific for a Pl Asp. 
TABLE IV 
Inhibition of Caspases by Aza-peptide Epoxides. 
k M-1 s-1 
inhibitor EP caspase-1 caspase-3 caspase-6 caspase-8 
22c Cbz-Val-AAsp-EP- s,s NA 3650 ± 570 350 ± 77 1260 ± 350 
COO Et 
22n Cbz-Val-AAsp-EP- s,s NA 1110±340 90 ± 18 370 ± 80 
COOH 
22a Cbz-Val-AAsp-EP- trans NA 310 ± 5 44 ± 9 180 ± 1 
CH2CH2Ph 
22b Cbz-Val-AAsp-EP- trans NA 145 ± 18 NI NI 
Ph-4-Cl 
23a PhPr-Val-Ala-AAsp- trans 300 ± 144 NA NA NA 
EP-CH2CH2Ph 
23c PhPr-Val-Ala-AAsp- s,s 32200 ± 14560 1040 ± 80 75 ± 15 1570 ± 235 
EP-COOEt R,R 6290 ± 1524 NI NI NI 
23d PhPr-Val-Ala-AAsp- trans 18070 ± 2625 680 ± 140 NA NA 
EP-COOCH2Ph s,s 52140 ± 5295 1470 ± 40 165 ± 30 1560 ± 110 
R,R 1860 ± 302 NI 15 185 
23e PhPr-Val-Ala-AAsp- s,s 56640 ± 9322 2110 ± 50 240 ± 14 3775 ± 630 
EP-COOCH2CH2Ph 
23f PhPr-Val-Ala-AAsp- s,s 1910 ± 370 142 ± 14 6050 ± 865 
EP-CONHCH2CH3 
23g PhPr-Val-Ala-AAsp- s,s 65900 ± 9153 1610 ± 5 155 ± 3 9360 ± 1570 
EP-CONHCH2Ph R,R 1630 ± 522 NI NI NI 
23h PhPr-Val-Ala-AAsp- s,s 17150 ± 2254 1110 ± 100 130 ± 10 10050 ± 1890 
EP-CONHCH2CH2Ph R,R 950 ± 51 NI NI NI 
23i PhPr-Val-Ala-AAsp- s,s 12260 ± 19 510 ± 100 63 ± 6 4090 ± 630 
EP-CONHCH2CH(OH)Ph R,R 400 ± 19 NI NI NI 
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TABLE IV-continued 
Inhibition of Caspases by Aza-peptide Epoxides. 
inhibitor EP caspase-1 caspase-3 caspase-6 caspase-8 
23j PhPr-Val-Ala-AAsp- s,s 13400 260 ± 25 25 ± 5 140 ± 60 
EP-CO-Ala-NHCH2 Ph R,R 268 ± 75 NI NI NI 
23k PhPr-Val-Ala-AAsp- s,s 26090 ± 2562 420 ± 6 71±14 315 ± 45 
EP-CO-Leu-NH2 
231 PhPr-Val-Ala-AAsp- s,s 32740 ± 9937 625 ± 160 65 ± 1 390 ± 126 
EP-CO-Phe-NH2 R,R 330 NI NI NI 
23m PhPr-Val-Ala-AAsp- s,s 3245 ± 2330 87 ±4 11 125 
EP-CO-Tyr-NH2 
24c Cbz-Glu-Val-AAsp- s,s 58500 50500 ± 2075 4185 195360 ± 24300 
EP-COOEt 
241 Cbz-Glu-Val-AAsp- R,R 1040 ± 455 470 ± 77 25 ± 5 NA 
EP-CO-Phe-NH2 
24h Cbz-Glu-Val-AAsp- s,s 41070 ± 440 27330 ± 5430 3135 ± 275 72750 ± 15000 
EP-CONHCH2CH2Ph 
25c Cbz-Asp-Glu-Val- s,s 11840 ± 1214 1074440 ± 154710 5440 ± 140 95480 ± 13000 
AAsp-EP-COOEt R,R 4320 ± 830 464420 ± 186300 475 785 ± 125 
251 Cbz-Asp-Glu-Val- s,s 9250 ± 2835 722180 ± 340860 6145 ± 535 29570 ± 4700 
AAsp-EP-CO-Phe-NH2 
25g Cbz-Asp-Glu-Val- s,s 25420 ± 4013 1097820 ± 94860 6000 ± 390 84390 ± 21600 
AAsp-EP-CONHCH2Ph 
25d Cbz-Asp-Glu-Val- s,s 54690 ± 15913 1915200 ± 209200 12700 ± 2075 188130 ± 52000 
AAsp-EP-COOCH2Ph 
26c Cbz-Leu-Glu-Thr- s,s 25730 3210 ±315 8620 61190 ± 6000 
AAsp-EP-COOEt R,R 19570 3250 ± 160 4390 34760 ± 6600 
26d Cbz-Leu-Glu-Thr- s,s 43500 ± 2150 3520 ± 600 10285 ± 690 727 50 ± 18000 
AAsp-EP-COOCH 2Ph 
26h Cbz-Leu-Glu-Thr- s,s NA 2550 ± 25 10040 ± 690 53275 ± 2220 
AAsp-EP-CONHCH2CH2 Ph 
26j Cbz-Leu-Glu-Thr- s,s NA 1280 ± 77 6660 ± 2200 44760 ± 2850 
AAsp-EP-CO-Ala-
NHCH2Ph 
27c Cbz-Ile-Glu-Thr- s,s 12372 4080 ± 360 45770 ± 4190 52800 ± 11000 
AAsp-EP-COOEt R,R 13260 ± 3684 2630 ± 365 34050 ± 1135 8800 ± 2750 
27d Cbz-Ile-Glu-Thr- s,s 45788 9545 ± 960 86230 ± 6640 58510 ±4950 
AAsp-EP-COOCH 2Ph R,R 13000 ± 980 3115 ± 125 45400 ± 1580 4560 ± 470 
27g Cbz-Ile-Glu-Thr- R,R 18140 ± 4085 6475 ± 240 60150 ± 2000 6525 ± 1100 
AAsp-EP-CONHCH2Ph 
27j Cbz-Ile-Glu-Thr- s,s NA 3050 38250 ± 2930 56055 ± 11975 
AAsp-EP-CO-Ala-
NHCH2Ph 
PhPr = Ph-CH2-CH2-CO-, 
NI =no inhibition, 
EP = epoxide, 
AAsp = aza-Asp, 
Cbz = Ph-CH2-CO-. 
45 
TABLEV 
Inhibition of Caspases by Aza-peptide Epoxides with Disubstituted Amides. 
k M-1s-1 
inhibitor EP caspase-1 caspase-3 caspase-6 caspase-8 
10-129 PhPr-Val-Ala-AAsp-EP- s,s 26150 ± 5460 520 ± 10 53 ± 9 650 ± 160 
CON(CH2CH2CH2CH3)o 
10-127 PhPr-Val-Ala-AAsp-EP- s,s 101140 ± 9547 830 ± 40 145 ± 1 1000 ± 125 
CON(CH2Ph)o 
11-4 Cbz-Leu-Glu-Thr-AAsp- s,s NA 2750 ± 205 13840 ± 270 60810 ± 685 
EP-CON(CH2Ph)o 
11-11 Cbz-Ile-Glu-Thr-AAsp- s,s NA 3550 32000 ± 1680 46780 
EP-CON(CH2Ph)o 
11-16 Cbz-Leu-Glu-Thr-AAsp- s,s NA 2640 ± 100 9680 ± 875 61950 ± 6680 
EP-CON(CH3)CH2 Ph 
11-17 PhPr-Val-Ala-AAsp-EP- s,s NA 1950 ± 150 136 3310 ± 650 
CON(CH3)CH2Ph 
11-18 Cbz-Ile-Glu-Thr-AAsp- s,s NA 4780 47730 ± 420 56860 ± 6275 
EP-CON(CH3)CH2 Ph 
US 8,013,014 B2 
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TABLE VI 




inhibitor R3 chemistry (nM) 
12a COO Et s,s 53 ± 25 
COO Et R,R 788 ± 88 
COO Et trans 
COO Et cis 
12b COOCH2 Ph s,s 47 ± 33 
COOCH2 Ph trans 
12c COOCH2 CH2 Ph s,s 45 
12d CONHCH2 Ph s,s NI 
12e CONHCH2 CH2 Ph s,s NI 
12f CO-Ala-NH-Bzl R,R NI 
12g CON(nBu)o s,s 68 ± 4 
12h CON(CH3)CH2Ph s,s 63 ± 11 
12i CH2CH2Ph trans 70 ± 14 
12j Ph-4-Cl trans 90 ± 0 













Legumain is inhibited by a variety of AAsn derivatives 
which are either not inhibitors for caspases or very poor. Both 
Schistosome and pig kidney legumain are inhibited. 
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interactions that are found in complexes of a particular 
enzyme with its substrates and/or inhibitors. Additional inter-
actions with the enzyme can be obtained by tailoring the R3 
group of the inhibitor to imitate the amino acid residues which 
5 are preferred by an individual protease at the S 1' and S2' 
subsites. For example, aza-peptide epoxides with R3 pheny-
lalkyl groups would interact effectively with caspase-1, 
which is shown to prefer such structures in alpha-ketoamide 
peptide inhibitors. Likewise, the M1 group can interact with 
10 the S subsites of the target cysteine protease. Once a good 
inhibitor structure for a particular enzyme is found, it is then 
possible to change other characteristics such as solubility or 
hydrophobicity by adding substituents to the M 1 or R1 and R2 
groups. 
15 The following structures are inhibitors for the listed 
enzymes. The inhibitor sequences were obtained from pep-
tide substrate and/or inhibitor sequences in the protease lit-
erature. 
C1-C6H4 CH20CO-Phe-AG!y-EP-COOH for papain 
20 C6H5 CH2NHCO-Gly-Phe-AG!y-EP-COOH for cathepsin B 
Morpholine-C0-2-N aphthyl-AHph-EP-COO Et for cathep-
sin S 
2-Naphthyl-S02-Ile-ATrp-EP-COOH for cathepsin B 
l-Naphthyl-S02-Val-ATrp-EP-COOH for cathepsin Band L 
25 Pro-Phe-AArg-EP-COOH for cathepsin Band L 
Cbz-Phe-Leu-Leu-AMet(02)-EP-COOH for cathepsin K 





Overall, the aza-peptide epoxide inhibitors have worked 
with every cysteine protease we have tested. The rates are 
higher with cysteine proteases that belong to clan CD com- 35 










COOCH2Ph for caspase-1 
for 
3. Inhibition Mechanism 
The active site of cysteine proteases contains a cysteine and 
40 Naphthyl-CH20CO-Val-Ala-AAsp-EP-COOCH2Ph 
caspase-1 
a histidine residue. The proposed mechanism involves the 
attack of the active site cysteine residue on the epoxide func-
tional group to form a covalent adduct. An example of a 
caspase inhibitor is shown in the following figure. The 
enzyme recognizes the Pl AAsp residue and inhibition 
occurs. Additional interactions would occur between the 
extended substrate binding site of the cysteine protease and 45 
the inhibitor which would increase the binding affinity and 
specificity of the inhibitors. 
for 
4-CF 3 -PhCH2CH2CO-Val-Ala-AAsp-EP-COOCH2Ph for 
caspase-1 
4-CH3 -PhCH2CH2CO-Val-Ala-AAsp-EP-COOCH2Ph for 
caspase-1 






The peptide and amino acid aza-peptide epoxide deriva-








55 C5H9---0CO-Asp-Glu-Val-AAsp-EP-COOEt for caspase-3 









65 Cbz-Leu-Glu-Thr-AAsp-EP-COOCH2C6H11 for caspase-8 
Cbz-Asp-Glu-Val-AAsp-EP-COO(CH2)2C6H4 -p-OCH3 for 
caspase-3 
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Cbz-Ala-Ala-AAsn-EP-COO(CH2 ) 2 -2-naphthyl for legu-
mam 
PhCH2CH2 CO-Val-Ala-AAsp-EP-(CH2 ) 2 Ph-3-F 
caspase-1 
for 
PhCH2CH2 CO-Val-Ala-AAsp-EP-COO( CH2 ) 2 -2-naphthy 1 
for caspase-1 
Cbz-Leu-Glu-Thr-AAsp-EP-COO(CH2 ) 2 C6H4 -p-N02 for 
caspase-6 
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linker, for example a cleavable linker to facilliate the removal 
of aza-peptide epoxide-protease conjugates. 
5. In Vivo Uses. 
Effective inhibitors of the proteolytic function of caspases 
(Tables IV and V) can be used to treat a variety of diseases. 
Excessive cell death can result from acquired or genetic con-
ditions which increase the accumulation of signals that 
induce apoptosis or that diminish the threshold at which such 
events induce apoptosis. Excessive apoptosis has been asso-Cbz-Ala-Ala-AAsn-EP-COO(CH2 ) 2 C6H4 -p-CN for legu-
mam 
PhCH2CH2 CO-Val-Ala-AAsp-EP-COO(CH2 ) 2 C6H4 -m-
O Ph for caspase-1 
2,4-dinitrophenyl-Ahx-Gly-Phe-AAla-EP-COOH for cathe-
psin L 
10 ciated with a variety of disease states including neurodegen-
erative disorders, ischemic injuries, acquired immunodefi-
ciency syndrome (AIDS), and osteoporosis. Apoptosis is 
involved in amyotrophic lateral sclerosis (ALS), Hunting-






15 spinal muscular atrophy. In multiple sclerosis (MS), the death 
of the oligodendrocytes is an important example of the glial 
degeneration through apoptosis. 
Huntingtin, the first protein identified as a caspase sub-
strate that is specifically involved in a neurodegenerative 
4. In Vitro Uses. 20 disease, is a substrate for proteolytic cleavage by caspase-3. 
Thus, aza-peptide epoxides would be useful for the treatment 
ofHuntington' s disease and other neurodegenerative diseases 
such as dentatorubropallidoluysian atrophy (DRPLA), 
spinocerebellar atrophy type 3 (SCA-3), and spinal bulbar 
To use the above inhibitors in vitro, they are dissolved in an 
organic solvent such as dimethylsulfoxide or ethanol, and are 
added to an aqueous solution containing serine and/or cys-
teine proteases. The final concentration of the organic solvent 
should be less than 25%. The inhibitors may also be added as 
solids or in suspension. The cysteine protease inhibitors of 
this disclosure would be useful in a variety of experimental 
procedures where proteolysis is a significant problem. Inclu-
sion of these inhibitors in radioimmunoassay experiments 
would result in higher sensitivity. The use of these inhibitors 
in plasma fractionation procedures would result in higher 
yields of valuable plasma proteins and would make purifica-
tion of the proteins easier. The inhibitors disclosed here could 
25 muscular atrophy (SBMA). 
Effector caspases cleave Alzheimer's gene products, pres-
enilins 1 and 2 proteins. Recently, it has been shown that 
caspase-6 is involved in human neuronal cell apoptosis, amy-
loidogenesis, and Alzheimer's disease. Amyloid ~ peptide 
30 (A~), which builds up in the brains of people with Alzhe-
imer's disease, causes cultured neurons to die by apoptosis. 
Thus effective caspase-6 aza-peptide epoxide inhibitors 
(Tables IV and V) can be used for the treatment of Alzhe-
imer's disease. be used in cloning experiments utilizing bacterial cultures, 
yeast, and human cells to produce a purified cloned product in 35 
higher yield. 
In models related to Parkinson disease, peptide caspase 
inhibitors protect against l-methyl-4-phenylpyridinium 
(MPP+)-induced apoptosis of cultured cerebellar granular 
neurons and increase the rate of survival. Also, in mice over-
expressing Bcl-2, dopaminergic l-methyl-4-phenyl-1,2,3,6-
The novel compounds of this disclosure are effective in the 
prevention of unnecessary proteolysis caused by cysteine 
proteases in the process of purification, transport and storage 
of peptides and proteins as shown in Tables I-VI by effective 
inhibition of many cysteine proteases. 
Diagnostic Reagents 
Aza-peptide epoxides of the present disclosure can be used 
for the identification of proteases, for example novel cysteine 
proteases. One embodiment provides a method for screening 
40 tetrahydropyridine (MPTP) caspase activity is blocked, tox-
icity is decreased, and substantial nigra neurons survive. 
Thus, effective caspase aza-peptide epoxide inhibitors (Table 
IV) can be used for the treatment of Parkinson's disease. 
Neuronal apoptosis is also seen after acute injuries such as 
45 stroke, trauma, and ischemia. Apoptosis has been observed in 
striatal and cortical neurons in animal models of stroke. a sample for the presence of a protease, particularly a cysteine 
protease, by contacting the sample with an aza-peptide 
epoxide, for example an aza-peptide epoxide of Formula I, 
and detecting the presence of the the aza-peptide epoxide-
protease conjugate. Detection of the conjugate may be 50 
accomplished using known techniques. For example, aza-
peptide epoxides of the present disclosure can be modified 
with a detectable label including but not limited to a radio-
isotope, fluorescent marker, biotin, antibody, enzyme conju-
gate such as horseradish peroxidase, or the like. The aza- 55 
peptide conjugates can be fixed to a support, for example 
using known chemical fixatives, and a sample can then by 
added to the aza-peptide epoxide. Such support can be 
microarrays or the like. The fixed aza-peptide epoxide can 
then irreverisible or reverisibly bind a protease, for example a 60 
cysteine protease, in the sample. The support can be washed 
to remove excess sample. The aza-peptide epoxide-protease 
conjugate can then be eluted from the support and the pro-
tease can be detected or identified using conventional tech-
niques. The support can be any durable substance including 65 
but not limited to metal, plastic, glass, quartz or the like. The 
aza-peptide epoxides can be linked to the support with a 
Transgenic mice, expressing a caspase-1 inhibitor, are pro-
tected from ischemic damage after middle cerebral artery 
occlusion. During ischemia, activated caspases dismantle the 
cell by cleaving multiple substrates such as the enzymes 
essential for cell repair and cytoskeletal proteins. Therefore, 
caspase activation develops in models of global ischemia and 
may accompany the ischemic component of head injury. The 
effect of irreversible inhibitors (Z-VAD-FMK, Z-DEVD-
FMK, and YVAD-CMK) on ischemia-induced tissue shows 
that caspase-1 and caspase-3 are involved in the mechanism 
of cell death in ischemic and excitotoxic brain injury. 
Caspases are recognized as novel therapeutic targets for cen-
tral nervous diseases in which cell death occurs mainly by the 
mechanism of apoptosis. Thus effective caspase aza-peptide 
epoxide inhibitors (Tables IV and V) can be used for the 
treatment of many diseases involving apoptosis. 
Effective caspase aza-peptide epoxide inhibitors are par-
ticularly useful for treatment of nerve degeneration associ-
ated with conditions and/or disorders including, but not lim-
ited to, neuropathies; idiopathic peripheral neuropathies; 
peripheral neuropathies due to genetic mutations; stroke; 
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Alzheimer's disease; Parkinson's disease; Huntington's dis-
ease, dentatorubropallidoluysian atrophy; spinocerebellar 
atrophy; spinal bulbar muscular atrophy; peripheral neuropa-
thies associated with uremia, rheumatologic diseases, liver 
diseases, or infections; axonal degeneration secondary to pri-
mary demyelinating disorders, inflammatory demyelinating 
neuropathies, multiple sclerosis, or chronic spinal cord 
degenerations; amyotrophic lateral sclerosis; a motor neuron 
disease; the presence of metabolic derangements such as 
diabetes or uremia, central or peripheral ischemia; genetic 10 
susceptibility to nerve degeneration; or exposure to a neuro-
toxic agent. Such neurotoxic agents include, but are not lim-
ited to, some an anti-cancer agents, especially those causing 
microtuble stabilixation or disruption. Some exemplary anti-
cancer drugs known to result in peripheral neuropathy 15 
include, but are not limited to, vincristine, cisplatin, and pacli-
taxel (Taxol®) 
Aza-peptide epoxides can be used to control protein turn-
over, muscular dystrophy, myocardial tissue damage, tumor 
metastasis, and bone resorption as shown in Table I by effec- 20 
tive inhibition of lysosomal cathepsin B in buffer. Peptide 
aza-peptide epoxides can also be used as neuroprotectants or 
for the treatment of ischemia, stroke, or Alzheimer's disease 
38 
Calpain inhibitors useful in alone or in combination with 
the aza-peptide epoxides of the present disclosure include, 
but are not limited to, calpain inhibitors with the formula: 
a pharmaceutically acceptable salt or prodrug thereof, 
wherein 
M1 is selected from the group consisting of H, NH2 -
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, X2N-
CO-, X-NH-CS-, X2N--CS-, X-NH-S02-, 
X2N-S02-, X--CO-, X--CS-, X-, Y-S02-, 
Y ---0-CO-, Y ---0---CS-, morpholine-CO-, and bioti-
nyl; 
X is selected from the group consisting of H, C1 _10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl monosubstituted with K, phenyl 
disubstituted with K, phenyl trisubstituted with K, naphthyl, 
naphthyl monosubstituted with K, naphthyl disubstituted 
with K, naphthyl trisubstituted with K, C1 _10 fluoroalkyl with 
an attached phenyl group, C1 _10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 
alkyl with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, as shown in Table I by effective inhibition of calpain I and 
calpain II. 
6. Treatment of Peripheral Neuropathy. 
Embodiments of the present disclosure describe composi-
tions and methods for the treatment of a pathology, in par-
ticular a neural pathology such as cytoskeletal degeneration 
25 cl-10 alkyl with an attachednaphthyl group, cl-10 alkyl with 
an attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phenoxy 
of peripheral neurons, peripheral neuropathy, or axonal 30 
degeneration including sensory neuron axonal degeneration. 
The neural pathology can be related to a disease or condition 
such as diabetes, or can be the result of contact with a chem-
cial agent including neurotoxic agents, such as certain anti-
cancer agents, including those listed above. One of the several 35 
embodiments of the present disclosure provides a method for 
treating a neural pathology of the peripheral nervous system, 
for example nerve degeneration, more specificially axonal 
degeneration, by administering to a patient a therapeutically 
effective amount of an aza-peptide epoxide, preferrably an 40 
aza-peptide epoxide capable of inhibiting caspases and/or 
cal pains. 
Axonal degeneration is a feature common to a wide spec-
trum of neurologic disorders, and axonal degeneration is the 
pathology that underlies clinical dysfunction in these disor- 45 
ders. These diseases include, but are not limited to, peripheral 
neuropathies due to genetic mutations; peripheral neuropa-
thies associated with other systemic diseases including ure-
mia, rheumatologic diseases, liver diseases, and infections; 
axonal degeneration secondary to primary demyelinating dis- 50 
orders including inflammatory demyelinating neuropathies 
and multiple sclerosis; and nerve degeneration associated 
with exposure to a neurotoxic agent, such as an anti-cancer 
agent. 
As demonstrated in the examples below, the aza-peptide 55 
epoxide compounds of the present disclosure are effective in 
preventing axonal degeneration in these and other disorders 
and will thus constitute a novel treatment for such diseases. In 
other embodiments, the aza-peptide epoxides of the present 
disclosure can be administered simultaneous with a calpain 60 
inhibitor that is also effective in treating nerve degeneration 
associated with the conditions listed above, among others. 
Embodiments of calpain inhibitors useful for treating nerve 
degeneration are discussed in greater detail in U.S. patent 
application Ser. No. 10/671,360, which is incorporated by 65 
reference herein in its entirety, along with their synthetic 
procedures and examples. 
group, and C1_10 alkyl monosubstituted with M
2
; 
Y is selected from the group consisting ofC1_10 alkyl, C3 _15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted with 
J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 9-fluore-
nyl, phenyl, phenyl monosubstituted with K, phenyl disubsti-
tuted with K, phenyl trisubstituted with K, naphthyl, naphthyl 
monosubstituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1 _10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 
alkyl with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attachednaphthyl group, cl-10 alkyl with 
an attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phenoxy 
group, M2 , and C1_10 alkyl monosubstituted with M
2
; 
M2 is selected from the group consisting of2-furyl, 2-tet-
rahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 
2-quinolinyl, 1-tetrahydroquinolinyl, 1-isoquinolinyl, 2-tet-
rahydroisoquinolinyl, and -N(CH2 CH2 ) 20; 
J is selected from the group consisting of halogen, C02 H, 
OH, CN, N02 , NH2 , C1 _10 alkoxy, C1 _10 alkylamino, C2 _12 
dialkylamino, C1 _10 alkyl-0---CO-, C1 _10 alkyl-0-CO-
NH-, C1_10 alkyl-S-, and -N(CH2CH2 ) 2 0; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1 _10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02 , CN, 
OH, C02 H, amino, C1_10 alkylamino, C2 _12 dialkylamino, 
C1_10 acyl, and C1 _10 alkoxy-CO-, and C1_10 alkyl-S-, and 
-N(CH2CH2 ) 2 0; 
AA 1 andAA 2 side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
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omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2---CH 
(CH2CHEt2)-C02H, alpha-aminoheptanoic acid, NH2- 5 
CH(CH2-l-naphthyl)-C02H, NH2---CH(CH2-2-naphthyl)-
C02H, NH2---CH(CH2-cyclohexyl)-C02H, NH2---CH 
(CH2-cyclopentyl)-C02H, NH2---CH(CH2-cyclobutyl)-
C02H, NH2---CH(CH2-cyclopropyl)-C02H, 
trifluoroleucine, 4-fluorophenylalanine, lysine substituted on 10 
the epsilon nitrogen with a biotinyl group, hexafluoroleucine, 
and NH2---CHR 
2 ---C02H; 
R2 is selected from the group consisting of C1_10 branched 
and unbranched alkyl, C1 _10 branched and unbranched 15 
cyclized alkyl, and C1_10 branched and unbranched fluoro-
alkyl; 
R3 and R4 are selected independently from the group con-
sisting of 
a) H, C1 _20 alkyl, C1 _20 cyclized alkyl, C1 _20 alkyl with a 20 
phenyl group attached to the cl-20 alkyl, cl-20 cyclized alkyl 
with an attached phenyl group, C1 _20 alkyl with an attached 
phenyl group monosubstituted with K, C1 _20 alkyl with an 
attached phenyl group disubstituted with K, C1 _20 alkyl with 
an attached phenyl group trisubstituted with K, C1_20 cyclized 25 
alkyl with an attached phenyl group monosubstituted with K, 
C1 _10 alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl, C1 _10 alkyl with a 
piperidine ring attached through nitrogen to the alkyl, cl-10 
alkyl with a pyrrolidine ring attached through nitrogen to the 30 
alkyl, C1 _20 alkyl with an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1 _10 with an attached 4-pyridyl 
group, cl-10 with an attached 3-pyridyl group, cl-10 with an 









R5 is selected from the group consisting of phenyl, phenyl 
40 
monosubstituted with J, phenyl disubstituted with J, phenyl 





2-quinolinyl monosubstituted with J, 1-isoquinolinyl, 1-iso-



















In particular, exemplary calpain inhibitors useful for treat-
1-naphthyl, 1-naphthyl monosubstituted with J, 1-naph-
thyl disubstituted with J, 2-naphthyl, 2-naphthyl mono-
substituted with J, 2-naphthyl disubstituted with J, 2-py-
ridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R6 is selected from the group consisting ofC1_4 alkyl, C1 _4 
alkyl substituted with phenyl, phenyl, and phenyl substituted 
with J; n=l-6; 
60 ing nerve degeneration alone, or in combination with the 
aza-peptide epoxide compounds include, but are not limited 
to the following: 
R7 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosubsti- 65 
tuted with J, 3-pyridyl, 3-pyridyl monosubstituted with J, 
4-pyridyl, 4-pyridyl monosubstituted with J, 2-quinolinyl, 
Z-Leu-Nva-CONHCH2-2-pyridyl, 
Z-Leu-Abu-CONHCH2CH(OH)C6F 5 , 
Z-Leu-Phe-CONH(CH2)2Ph, 
Z-Leu-Abu-CONHCH2CH(OH)C6H4 -3-0C6Hi3-CF 3 ), 
Z-Leu-Abu-CONHCH2CH(OH)C6H4 ( 4-0CH2Ph), 
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Z-Leu-Abu-CONHCH2 CH(OH)C6H4 ( 4-0Ph), 
Z-Leu-Phe-CONHCH2 -2-quinoliny 1, 
Z-Leu-Abu-CONH(CH2 ) 2C6Hi3-0CH3), 
Z-Leu-Abu-CONH(CH2 ) 2C6Hi 4-0CH3 ), 
Z-Leu-Abu-CONHCH2 CH(OH)- l-C10H7 , 
Z-Leu-Phe-CONH( CH2 ) 3 -4-morpholinyl, 
Z-Leu-Abu-CONH(CH2 ) 2C6H4 (2-0CH3 ), 
Z-Leu-Abu-CONHCH2 -2-quinolinyl, 
Z-Leu-Abu-CONH(CH2 ) 3 -4-morpholinyl (AK295), 
Z-Leu-Abu-CONH(CH2 ) 2 -2-(N-methylpyrrole), 
Z-Leu-Phe-CONHCH2CH( 0 H)C6H4 -3-0C6H4 (3-CF 3 ), 
Z-Leu-Abu-CONH(CH2 ) 2 C6H5 , 
Z-Leu-Phe-CONH-Et, 
Z-Leu-Abu-CONHCH2 CH(OC2 H5 ) 2 , 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-0Ph), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-0CH2Ph), 
Z-Leu-Abu-CONHCH2 C6H5 , 
Z-Leu-Phe-CONH( CH2 ) 2 NH-biotiny 1, 
Z-Leu-Phe-CONH(CH2 ) 3 -2-tetrahydroisoquinolinyl, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H3 (3,4-(0CH2Ph)2 ), 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 ( 4-0CH3 ), 
Z-Leu-Nva-CONH(CH2 ) 3 -4-morpholinyl, 
Z-Leu-Abu-CONHCH2 - l -isoquinoliny 1, 
Z-Leu-Abu-CONHEt, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 -3-0C6H3 (3,4-C12), 
Z-Leu-Abu-CONHMe, 
Z-Leu-Abu-CONH(CH2k 1-imidazolyl, 
Z-Leu-Abu-CONH(CH2 ) 2 -3-indolyl, 
Z-Leu-Abu-CONH( CH2 ) 3 -2-tetrahydroisoquinoliny 1, 
Z-Leu-Abu-CONHCH2 -2-tetrahydrofuryl, 
Z-Leu-Abu-CONHCH2 CH(O H)C6H4 ( 4-N ( CH3 ) 2 ), 
Z-Leu-Phe-CONH-n-Pr, 
Z-Leu-Abu-CONHCH2 CH(OH)-2-C10H7 , 
Z-Leu-Phe-CONH-Me, 
Z-Leu-Abu-CONHCH2 CH(O H)C6H4 (3-CF 3 ), 
Z-Leu-Abu-CONH(CH2 ) 3 - l-tetrahydroquinolinyl, 
Z-Leu-Abu-CONH(CH2 ) 2C6Hi 4-0H), 
Z-Leu-Abu-CONHCH2 CH(OH)C6H2 (3,4,5-(0CH3 ) 3 ), 
Z-Leu-Phe-CONH(CH2 ) 3 - l-tetrahydroquinolinyl, 
Z-Leu-Abu-CONH(CH2 ) 2 -2-pyridyl, 
Z-Leu-Abu-CONHCH2---C6Hil,3,3-(CH3 ) 3 -5-0H), 
Z-Leu-Phe-CONHCH2CH(OH)C6H4 (3-CF3), 
Z-Leu-Phe-CONHCH2CH(OH)C6H3 (3,4-(0CH2 Ph)2 ), 
Z-Leu-Abu-CONH(CH2 ) 50H, 
Z-Leu-Abu-CONHCH2 CH(OCH3 ) 2 , 
Z-Leu-Phe-CONHCH2CH(OH)C6H4 -3-0C6H3 (3,4-C12), 
Z-Leu-Phe-CONHCH2CH(OH)C6H4 (3-0Ph), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-N(CH3 ) 2 ), 
Z-Leu-Abu-CONHCH2 -2-pyridyl, 
Z-Leu-Abu-CONH(CH2 ) 20(CH2 ) 20H, 
Z-Leu-Phe-CONHCH2 -2-pyridyl, 
Z-Leu-Abu-CONH(CH2 ) 2NH-biotinyl, 
Z-Leu-Abu-CONHCH2---C6H11 , 
Z-Leu-Phe-CONHCH2CH(OH)C6F 5 , 
Z-Leu-Abu-CONHCH2 -2-furyl, 
Z-Leu-Abu-CONH(CH2 ) 3C6H5 , 
Z-Leu-Abu-CONH(CH2 ) 20H, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 (3-0Ph), 
Z-Leu-Abu-CONH( CH2 ) 2 -4-morpholiny 1, 
Z-Leu-Abu-CONHCH2 CH(OH)Ph, 
Z-Leu-Abu-CONHCH2 -4-pyridyl, 
Z-Leu-Abu-CONH( CH2k l -pyrrolidine-2-one, 
Z-Leu-Phe-CONHCH2CH(OH)Ph, 





Z-Leu-Abu-CONHCH2 -3-pyridyl, and 
Z-Leu-Phe-CONHCH2 Ph. 
Exemplary calpain inhibitors for use in combination with 
the aza-peptide epoxide compounds of the present disclosure 
5 include, but are not limited to, peptide alpha-keto amides such 
as Z-Leu-Abu-CONH-(CH2k4-morpholinyl (AK295). 
Additionally, the aza-peptide epoxides of the present disclo-
sure, particularly those effective at caspase and/or calpain 
inhibition, can be administered, alone or in combination with 
10 a calpain inhibitor (e.g. AK295), simultanously with the 
administration of an anti-cancer drug, particularly an anti-
cancer drug known to induce nerve degeneration. In an exem-
plary embodiment, an aza-peptide epoxide caspase inhibitor, 
15 
preferrably of the formula Cbz-Asp-Glu-Val-AAsp-EP-
COOEt (JG36) is combined with a peptide alpha-keto amide 
calpain inhibitor, preferrably AK295. In another exemplary 
embodiment, an aza-peptide epoxide caspase inhibitor, alone 
or in combination withAK295, is administered to a mamma-
20 lian host, for example, a patient, undergoing chemotherapy 
with an anti-cancer agent including, but not limited to, vinc-
ristine, cisplatin, and paxlitaxel (Taxol®). 
As discussed in greater detail in Example 6, below, both the 
aza-peptide epoxide caspase inhibitor Cbz-Asp-Glu-Val-
25 AAsp-EP-COOEt (JG36) and the the peptide ketoamide 
calpain inhibitor Cbz-Leu-Abu-CONH-(CH2 k4-mor-
pholinyl (AK295) inhibited vincristine-induced axonal 
degeneration in rat dorsal root ganglia (DRG) cutlures in 
vitro. These results demonstrate the usefulness of these and 
30 similar compounds, (individually and in combination) for use 
in treating and/or preventing other neurotoxin-induced 
peripheral neuropathies, as well as other neural pathologies. 
35 
7. Drug Delivery. 
This disclosure also provides a pharmaceutical composi-
tion which comprises a compound according to Formula I and 
a pharmaceutically accepted carrier, dilutent or excipient. 
Accordingly, the compounds of Formula I may be used in the 
manufacture of a medicament. For therapeutic use, the pep-
40 tide aza-peptide epoxides may be administered orally, topi-
cally, or parenterally. The term parenteral, as used, includes 
subcutaneous injection, intravenous, intramuscular, intraste-
mal injection, or infusion techniques. The dosage depends 
primarily on the specific formulation and on the object of the 
45 therapy or prophylaxis. The amount of the individual doses as 
well as the administration is best determined by individually 
assessing each case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for example, 
50 as tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or granules, emulsions, hard or soft cap-
sules, syrups, or elixirs. Dosage levels of the order of0.2 mg 
to 140 mg per kilogram of body weight per day are useful in 
the treatment of the above-indicated conditions (10 mg to 7 
55 gms per patient per day). The amount ofactive ingredient that 
may be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of the peptide aza-
60 peptide epoxides or their pharmaceutically acceptable salts 
will normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular, or subcutaneous injection. Accordingly, pharma-
ceutical compositions for parenteral administration will con-
65 tain from about 10 mg to 7 gms of the compounds per dose. In 
addition to the active ingredient, these pharmaceutical com-
positions will usually contain a buffer, e.g. a phosphate buffer, 
US 8,013,014 B2 
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which keeps the pH in the range from 3.5 to 7, and sodium 
chloride, mannitol, or sorbitol for adjusting the isotonic pres-
sure. 
A composition for topical application can be formulated as 
an aqueous solution, lotion, jelly or an oily solution or sus- 5 
pension. A composition in the form of an aqueous solution is 
obtained by dissolving the compounds of this disclosure in 
aqueous buffer solution of pH 4 to 6.5 and, if desired, adding 
a polymeric binder. An oily formulation for topical applica-
tion is obtained by suspending the compounds of this disclo-
10 
sure in an oil, optionally with the addition of a swelling agent 




CH2COO-tBu, with 5 (Y =COO Et), was accomplished using 
the mixed anhydride method. To a solution of 5 ( 5 eq) in DMF 
at 0° C. was added N-methylmorpholine (NMM, 5 eq) fol-
lowed isobutyl chloroformate (IBCF, 5 eq). Afterthe reaction 
mixture was allowed to stir for 30 min, the substituted 
hydrazide (1 eq) dissolved in DMF was added to the mixture. 
After 10 min the ice bath was removed and the reaction was 
stirred for 16 hr at room temperature. The DMF was evapo-
rated and the residue was washed and purified using the same 
procedure as described above for the EDC/HOBT coupling. 
MS and 1 H NMR (DMSO-d6 or CDC13 ) were consistent with 
the proposed structures. Examples 3A-3I were prepared 
using this mixed anhydride method 
Example3A The following detailed examples are given to illustrate the 15 
present disclosure and are not intended to limit it in any 
manner. Examples describing the synthesis and composition Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-
EP-COOEt was purified using column chromatography on 
silica gel using 2:18:5 MeOH:CH2Cl2:EtOAc as the eluent; 
20 white solid, yield 58%. 
of additional aza-peptide epoxide compounds are included in 
U.S. patent application Ser. No. 10/603,054, which is hereby 
incorporated herein by reference in its entirety. 
Example 1 Example3B 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2R, 
25 3R)-EP-COOEt was purified using colunm chromatography 
on silica gel using 2:18:5 MeOH:CH2Cl2:EtOAc as the elu-
ent; white solid, yield 57%. 
Pentafluorophenol Coupling Method. (2R,3R)-3-(N2-(N-
Benzy loxycarbony lleucy 1-t-butoxyglutamy lthreony 1)-N 1 -t-
butoxycarbonylmethy lhydrazinocarbony l)oxirane-2-car-
boxylic Acid Ethyl Ester (Cbz-Leu-Glu(O-tBu)-Thr-AAsp 
(O-tBu)-(2R,3R)-EP-COOEt). Coupling ofCbz-Leu-Glu(O-
tBu)-Thr-NH-NH-CH2COO-tBu with 5 (Y=COOEt) 
was accomplished using the pentafluorophenol method. The 
epoxide 5 (1 eq, Y=COOEt) in DMF was reacted with pen- 30 
tafluorophenol (1 eq) and DCC (1 eq) in DMF at 0° C. The 
reaction was allowed to reach room temperature and then was 
stirred for 24 hours. Dicyclohexylurea was removed by fil-
tration and the filtrate was evaporated to dryness under 
reduced pressure. The peptide Cbz-Leu-Glu(O-tBu)-Thr- 35 
NH-NH--CH2COO-tBu (1 eq) in DMF was added to the 
residue and the reaction was allowed to stir at room tempera-
ture for 24 hours. The solvent was evaporated and the product 
was purified by chromatography using two silica gels col-
unms, the first colunm with 1 :9 MeOH:CH2Cl2 as the eluent, 40 
followed by another colunm with 2: 1 EtOAc:hexane as the 
eluent; white solid, yield 16%. MS and 1H NMR (CDC13 ) 
were consistent with the proposed structure. 
Example3C 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
COOEt was purified by chromatography on two successive 
columns, using 1:13 MeOH:CH2Cl2 as the eluent, followed 
by colunm chromatography using 2:1 EtOAc:hexane as the 
eluent; white solid, yield 44%. 
Example 3E 
Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-EP-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 7:13:1:1 hexane:EtOAc:MeOH:CH2Cl2 as the elu-
ent, and thenrechromatographed using 3:1 EtOAc:hexane as 
the eluent; white solid, yield 35%. MS (ESI) m/z 782.4 [(M+ 
1 tl. 1 H NMR (CDC13 ): 0.95 ( d, 6H, Val), 1.45 (s, 18H, tBu), 
Example 2 45 
1.90-2.30 (m, 3H, Val and Glu), 2.45 (m, 2H, Glu), 2.72 (t, 
2H, NHCH2CH2Ph), 3.40 and 3.60 (m, 2 H, NHCH2CH2Ph), 
3.50 and 3.8 (d, 2H, epoxy), 4.10-4.30 (m, 4H, NCH2 and 
(a-H), 5.10 (m, 2H, Cbz), 6.10 and 6.25 (m, 2H, NH), 7.20-
7.40 (m, SH, Ph), 9.00 (m, lH, NH). 
Mixed Anhydride Coupling Method. Coupling of bulky 
peptides, such as Z-Asp(O-tBu)-Glu(O-tBu)-Val-NH-
NH2--COO-tBu and Cbz-Leu-Glu(O-tBu)-Thr-NH-NH-
CH2COO-tBu, with 5 (Y =COO Et), was accomplished using 50 
the mixed anhydride method. To a solutionof5 (5 eq) inDMF 
at 0° C. was added N-methylmorpholine (NMM, 5 eq) fol-
lowed isobutyl chloroformate (IBCF, 5 eq). Afterthe reaction 
mixture was allowed to stir for 30 min, the substituted 
hydrazide (1 eq) dissolved in DMF was added to the mixture. 55 
After 10 min the ice bath was removed and the reaction was 
Example 3F 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-
EP-COOCH2Ph was obtained using the mixed anhydride 
coupling method, and purified using colunm chromatography 
on silica gel using 5:1:19 EtOAc:MeOH:CH2Cl2 as the elu-
ent; white solid, yield23%. MS (ESI)m/z 940.5 [(M+ltJ. 1H 
NMR (CDC13 ): 0.85 (m, 6H, Val), 1.35 (m, 27H, tBu), 1.80-
2.24 (m, 3H, Val and Glu), 2.41 (m, 2H, Glu), 2.65-2.90 (m, 
2H, Asp), 3.60 and 4.00 (d, 2H, epoxy), 4.05-4.12 (m, 2H, 
stirred for 16 hr at room temperature. The DMF was evapo-
rated and the residue was washed and purified using the same 
procedure as described above for the EDC/HOBT coupling. 
MS and 1 H NMR (DMSO-d6 or CDC13 ) were consistent with 
the proposed structures. Examples 3A-3C were prepared 
using this mixed anhydride method. 
60 NCH2), 4.10-4.40 (m, 3H, a-H), 5.05 (m, 4H, Cbz), 6.05 (m, 
lH, NH), 7.20-7.40 (m, !OH, Ph), 7.85 (m, 2H, NH), 9.05 (m, 
lH, NH). 
Example 3 
Mixed Anhydride Coupling Method. Coupling of bulky 




EP-CONHCH2Ph was obtained using the mixed anhydride 
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coupling method and was purified using column chromatog-
raphy on silica gel using 1:2 EtOAc:hexane as the eluent; 
white solid, yield 31%. MS (ESI) m/z 939.6 [(M+lt]. 1H 
NMR (CDC13 ): 0.97 (m, 6H, Val), 1.40 (m, 27H, tBu), 1.9-2.3 
(m, 3H, Val and Glu), 2.41 (m, 2H, Glu), 2.80-2.9S (m, 2H, 5 
Asp), 3.63 and3.97 (d, 2H, epoxy), 4.0S-4.22 (m, 4H, NCH2), 
4.20-4.SS (m, 3H, a-H), 4.4S (m, 2H, NHCH2Ph), S.OS (m, 
2H, Cbz), 7.20-7.40 (m, !OH, Ph), 6.lS (m, lH, NH), 6.60 
46 
710.2S209. Observed m/z 7l0.2SSO. Anal. Calcd. for 
C30H39N5 0 15 .1.6SH20: C, 48.73; H, S.76; N, 9.47. Found: 
C, 48.73; H, S.63; N, 9.4S. 
Example4B 
(2R,3 R )-3-(N'-(N-Benzy loxycarbonylasparty 1-
glutamy lvaly 1)-N'-carboxymethy lhydrazinocarbony l)ox-
irane-2-carboxy lic Acid Ethyl Ester (Cbz-Asp-Glu-Val-(lH, NH), 7.8S (m, 2H, NH). 
Example3H 
Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-EP-COOEt 
lO AAsp-(2R,3R)-EP-COOEt). 1 H NMR (DMSO-d6): 0.84 (m, 
6H, Val), 1.20, 1.21 (t, 3H, OCH2CH3 ), 1.7-2.1 (m, 3H, Val, 
Glu), 2.21(m,2H, Glu), 2.40-2.6S (m, 2HAsp), 3.S8 and4.10 
(d, 2H, epoxy), 4.0S-4.22 (m, 4H, NCH2COOH and 
OCH2CH3 ), 4.S0-4.60 (m, 3H, a-H), S.OS (m, 2H, Cbz), was obtained using the mixed anhydride coupling method and 
was purified using colunm chromatography on silica gel with 
1:2 EtOAc:hexane as the eluent, and recrystallized from 
EtOAc/hexane; white solid, yield 44%. MS (ESI) m/z 706.1 
[(M+ltJ. 1H NMR (DMSO-d6 ): 0.90 (m, 6H, Val), 1.20 (t, 
3H, OCH2CH3 ), 1.40 (m, 18H, tBu), 1.60-2.00 (m, 3H, Val 20 
and Glu), 2.21 (m, 2H, Glu), 3.SO and 3.98 (d, 2H, epoxy), 
4.00-4.20 (m, 4H, NCH2 and OCH2CH3 ), 4.20-4.40 (m, 2H, 




15 7.20-7.40 (m, SH, Ph), 7.60 (lH, NH), 7.8S (m, 2H, NH), 
11.00 (m, COOH). HRMS (FAB) Calcd. for C30H39N5 0 15 : 
710.2S209. Observed m/z 7l0.2Sl9S. Anal. Calcd. for 
C30H39N5 0 15 .0.9H20: C, 49.64; H, S.66; N, 9.6S. Found: C, 
49.S9; H, S.S6; N, 9.66. 
Example S 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylaspartyl-
glutamy lvaly 1)-N1 -carboxymethy lhydrazinocarbony l)ox-
25 irane-2-carboxylic Acid Benzyl Ester (Cbz-Asp-Glu-Val-
AAsp-(2S,3S)-EP-COOCH2Ph). 1 H NMR (DMSO-d6 ): 0.8S 
(m, 6H, Val), 1.80-2.24 (m, 3H, Val, Glu), 2.41 (m, 2H, Glu), 
2.6S-2.90 (m, 2H, Asp), 3.60 and 4.00 (d, 2H, epoxy), 4.0S-
4.12 (m, 2H, NCH2COOH), 4.10-4.40 (m, 3H, a-H), S.OS (m, was obtained using the mixed anhydride coupling method and 
was purified using colunm chromatography on silica gel with 
7:13:1:19 hexane:EtOAc:MeOH:CH2Cl2 as the eluent, and 
then rechromatographed using 3: 1 EtOAc:hexane as the elu-
ent; white solid, yield3S%. MS (ESI)m/z706.1[(M+ltJ. 1H 
NMR (CDC13 ): 0.94 (m, 6H, Val), 1.21 (t, 3H, OCH2CH3 ), 
1.43 (m, 18H, tBu), 1.60-2.00 (m, 3H, Val and Glu), 2.21 (m, 35 
2H, Glu), 3.60 and 3.98 (d, 2H, epoxy), 4.00-4.20 (m, 4H, 
NCH2 and OCH2CH3 ), 4.20-4.40 (m, 2H, a-H), S.10 (m, 2H, 
Cbz), 7.20-7.40 (m, SH, Ph), 8.00 (m, 2H, NH). 
30 4H, Cbz), 6.0S (m, lH, NH), 7.20-7.40 (m, !OH, Ph), 7.8S (m, 
2H, NH), 9.0S (m, lH, NH). HRMS (ESI) Calcd. for 
C47H66N5 0 15 : 940.S. Observed m/z 940.S. Anal. Calcd. for 
C35H41N5 0 15 .1.SH20: C, S2.60; H, S.SS; N, 8.76. Found: C, 
S2.S9; H, S.37; N, 8.76. 
Example 6 
The peptide ketoamide calpain inhibitor Cbz-Leu-Abu-
CONH-(CH2k4-morpholinyl (AK29S) and the aza-pep-
40 tide epoxide caspase inhibitor Cbz-Asp-Glu-Val-AAsp-EP-Example 4 
COOEt (JG36) inhibit vincristine-induced nerve 
Deblocking of the t-Butyl Group in Aza-Asp Peptides. degeneration. 
Epoxysuccinyl peptides (PhPr-Val-Ala-AAsp(O-tBu)-trans-
EP-COOCH2Ph), (PhPr-Val-Ala-AAsp(O-tBu)-trans-EP-




COOEt), and peptidyl-AAsp(O-tBu)-EP-R3 derivatives all 
were separately reacted with TFA at 0° C. for 1 h-1.S hr. The 
excess TFA was removed under vacuum, and the final prod- 50 
ucts were recrystallized from methanol/ether and ether/hex-
ane to give the final epoxysuccinyl peptides as white solids 
(yields S9-8S% ). The products of these reactions are listed in 
Examples 4A-B. 
Dorsal Root Ganglia (DRG) Cultures. Tissue culture 
dishes (Falcon) of 3Sxl 0 mm were pre-coated with rat tail 
collagen (type 1, Sigma), air dried and rehydrated with 
DMEM (GIBCO) overnight at room temperature and then 
stored at 4° C. On the day ofDRG culture, the dishes were 
washed twice with PBS buffer (pH 7.4), filled with SSO µl 
medium and pre-incubated at 37° C. for at least 2 hours. 
Fifteen-day old embryos (El S) were removed from pregnant 
Sprague-Dawley rats (Charles River), and spinal cords with 
Example4A 
(2S,3S)-3-(N-(N-Benzyloxycarbonylaspartyl-
glutamy lvaly 1)-N-carboxymethylhydrazinocarbony 1 )ox-
irane-2-carboxy lic Acid Ethyl Ester (Cbz-Asp-Glu-Val-
AAsp-(2S,3S)-EP-COOEt). 1H NMR (DMSO-d6 ): 0.84 (m, 
6H, Val), 1.20, 1.21 (t, 3H, OCH2CH3 ), 1.7-2.1 (m, 3H, Val, 
Glu), 2.21(m,2H, Glu), 2.40-2.6S (m, 2HAsp), 3.S8 and4.10 
(d, 2H, epoxy), 4.0S-4.22 (m, 4H, NCH2COOH and 
OCH2CH3 ), 4.S0-4.60 (m, 3H, a-H), S.OS (m, 2H, Cbz), 
7.20-7.40 (m, SH, Ph), 7.60 (lH, NH), 7.8S (m, 2H, NH), 
11.00 (m, COOH). HRMS (FAB) Calcd. for C30H39N5 0 15 : 
55 cervical and thoracic DR Gs attached were dissected into L-1 S 
medium (GIBCO). Ganglia were separated from the spinal 
cord, stripped of their connective tissue sheaths and roots, and 
then pooled and washed twice with PBS buffer (pH 7.4). 
DR Gs were plated ( 4 per dish) in culture media and incubated 
60 at 37° C. in S% carbon dioxide for 4 hours to allow DRGs to 
attach to the substrate. Medium was then added to bring the 
total volume to 1 mL. Standard media was MEM (GIBCO, 
free calcium 1.8 mM), supplemented with 1%N2 supplement 
(GIBCO), 7S NGF (Alomone Labs, Jerusalem, Israel) 100 
65 ng/mL, and 1.4 mM L-glutamine (Sigma). Calcium-free 
medium was prepared in the same manner, replacing MEM 
with S-MEM (GIBCO). 
US 8,013,014 B2 
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Example6B 
Immunostaining of DRGs. At the end of the treatment 
period (see below) DRGs were fixed for 30 minutes with 4% 
paraformaldehyde. Cultures were then rinsed with 0.1 M TBS 
buffer, and treated sequentially with 3% H20 2, TBS-Triton, 
and 4% normal goat serum (NGS), each for 30 minutes at 
room temperature. DR Gs were incubated at 4 ° C. overnight in 
monoclonal antibody to MAPS (1 :500, Sigma). After wash-
ing in TBS-Triton, DRGs were incubated for 60 minutes in 10 
biotinylated secondary antibody, rinsed with TBS and reacted 
with avidin-biotin complex solution (ABC; Vector Labs) for 
one hour. Color was generated by incubation for 10 minutes 
in diaminobenzidine (DAB) solution, enhanced by addition 
of0.025% cobalt chloride and 0.02% nickel ammonium sul- 15 
fate. Stained tissue was rinsed, air dried and coverslipped for 
microscopy with Crystal/Mount (Biomeda). 
Example6C 
Vincristine Neuropathy. DRGs were allowed to mature for 
5 days (media change on day 3) creating a lush halo of 
neurites. This method of allowing neuritic extension to pro-
ceed before addition of a neurotoxin tests the effect of the 
toxin on established neurites as opposed to the effect on 
primary neuritic outgrowth. Thus, the in vitro paradigm is 
partially comparable to the clinical situation in that an "estab-
lished" peripheral nervous system is exposed to a toxic agent. 
After day 5 of culture, the media was changed to that 




as treatment day 0. Cultures were monitored and imaged daily 
using video microscopy. Vincristine sulfate salt (Sigma) was 
dissolved in culture medium, aliquoted and stored at -20° C. 
AK295 (the peptide ketoamide calpain inhibitor Cbz-Leu-
Abu-CONH-(CH2k4-morpholinyl) or JG36 (the aza-pep- 35 
tide epoxide caspase inhibitor Cbz-Asp-Glu-Val-AAsp-EP-
COOEt) was dissolved in 100% DMSO and then diluted to its 
final concentration with culture medium; the final concentra-
tion ofDMSO was <0.05%. 
48 
lyzed using NIH Image version 1.61. DRG areas were calcu-
lated by tracing the outside circumference of the remaining 
culture halo. The length of the longest neurite of each DRG 
was measured from the center of the DRG to the distal end of 
the neurite, so that cultures without remaining neurites still 
had positive values. These quantitative data were subjected to 
ANOVA, with post-test correction for multiple comparisons. 
As shown in the table and graph below, both AK295 and 
JG36 showed significant and equivalent protection against 
axonal degeneration in the DRG model of vincristine neur-
opathy. AK295 has also shown protection against Taxol neu-
ropathy in an animal model. These experiments indicate that 
a combination of a caspase inhibitor and a calpain inhibitor 
would give signicant protection against peripheral neuropa-
thy induced by toxic anticancer agents. 
TABLE XII 
Inhibition of nerve degeneration by AK295 and JG36 
p-value 
TREATMENT DRG AREA(% day 0) (vs. vin alone) 
AK295-50 µM 57.65 +/- 2.97 0.0278 
JG36-50 µM 55.53 +/- 2.56 0.0411 
AK295 + JG36-, both at 50 µM 51.62 +/- 7.66 0.0628 
Ak295 + JG36, both at 25 µM 49.43 +!- 10.31 0.2063 
Vin alone 35.96 +!- 7.25 
control 275.8 +/- 57.91 
The above specification and Examples fully disclose how 
to make and use the compounds of the present disclosure. 
However, the present disclosure is not limited to the particular 
embodiments described hereinabove, but includes all modi-
After 6 days of treatment (11 days in culture) immun-
ostained DRGs were quantitated for degree of axonal degen-
eration. Images of the DR Gs and neurites were captured onto 
disk using a computerized video imaging system, and ana-
40 fications thereof within the scope of the following claims. The 
various references to journals, patents, and other publications 
which are cited herein comprise the state of the art and are 
incorporated herein by reference. 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
SEQUENCE LISTING 
<223> OTHER INFORMATION: consenus active site motif for caspases 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, X ~ R, Q, OR G 
<400> SEQUENCE, 1 
Gln Ala Cys Xaa Gly 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 4 
<212> TYPE, PRT 
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-continued 
<213> ORGANISM, artificial 
<220> FEATURE, 
<223> OTHER INFORMATION: caspase recognition sequence 
<400> SEQUENCE, 2 
Trp Glu His Asp 
1 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, caspase group II recognition sequence 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 3 
Asp Glu Xaa Asp 
1 
<210> SEQ ID NO 4 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, caspase group III recognition sequence 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, X ~ V OR L 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 4 
Xaa Glu Xaa Asp 
1 
What is claimed is: 
1. A method of alleviation or stabilization of nerve degen-
eration in a mammal comprising: 
administering to a mammal in need thereof a therapeutically 45 
effective amount ofa compound of the formula: 
50 
or a pharmaceutically acceptable salt, or prodrug, thereof 55 
wherein, 
R1 is selected from the group consisting ofM1 , M2-AA1 , 
M2-AA2-AA1 , and M2-AA3 -AA2-AA1 ; 
M1 is selected from the group consisting ofNH2--CO-, 
NH2--CS-, NH2-S02-, X-NH--CO-, X2N- 60 
CO-, X-NH--CS-, X2N--CS-, X-NH-
S02-, X2N-S02-, X-CO-, X-CS-, 
Y-S02-, Y---0---CO-, Y-0---CS-, phenyl sub-
stituted with K, phenyl disubstituted with K, and mor-
pholine-CO-; 65 
M2 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, 
X2N-CO-, X-NH--CS-, X2N--CS-, 
X-NH-S02-, X2N-S02-, X-CO-, X--CS-, 
Y-S02-, Y---0---CO-, Y-0---CS-, phenyl, phe-
nyl substituted with K, phenyl disubstituted with K, and 
morpholine-CO-; 
X is selected from the group consisting of H, C1 _10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl sub-
stituted with J, cl-10 fluoroalkyl substituted with J, 1-ad-
mantyl, 9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted with 
K, naphthyl, naphthyl substituted with K, naphthyl dis-
ubstituted with K, naphthyl trisubstituted with K, C1_10 
fluoroalkyl with an attached phenyl group, cl-10 alkyl 
with an attached phenyl group, cl-10 alkyl with two 
attached phenyl groups, cl-10 alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with two 
attached phenyl groups substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, biotinyl, and cl-10 
alkyl with an attached phenoxy group substituted with K 
on the phenoxy group; 
Y is selected from the group consisting ofC1_10 alkyl, C3 _15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, phenyl 
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disubstituted with K, phenyl trisubstituted with K, naph-
thyl, naphthyl substituted with K, naphthyl disubstituted 
with K, naphthyl trisubstituted with K, C1_10 fluoroalkyl 
with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group, cl-10 alkyl with two attached 5 
phenyl groups, cl-10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with two attached 
phenyl groups substituted with K, C1_10 alkyl with an 
attached naphthyl group, C1_10 alkyl with an attached 
naphthyl group substituted with K, C1_10 alkyl with an 10 
attached phenoxy group, biotinyl, and cl-10 alkyl with 
an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, 15 
C2_12 dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl-
0---CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, 
CN, OH, C02H, amino, C1_10 alkylamino, C2_12 dialky- 20 
!amino, C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 
alkyl-S-; 
AAv AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 25 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, beta-ala- 30 
nine, norleucine, norvaline, alpha-aminobutanoic acid, 
epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxy-
lic acid, 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 0-eth- 35 
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)--C02H, alpha-ami-
noheptanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, 
NH2--CH(CH2-2-naphthyl)-C02H, NH2-CH(CH2-
cyclohexyl)-C02H, NH2-CH(CH2-cyclopentyl)- 40 
C02H, NH2--CH(CH2-cyclobutyl)-C02H, NH2--CH 
(CH2-cyclopropyl)-C02H, trifluoroleucine, 
4-fluorophenylalanine, lysine substituted on the epsilon 
nitrogen with a biotinyl group, and hexafluoroleucine; 
R2 is selected from the group consisting of C1_10 alkyl, 45 
cl-10 alkyl substituted with Q, cl-10 alkyl substituted 
with phenyl, C1_10 alkyl with an attached phenyl substi-
tuted with K, C1_10 alkyl substituted withnaphthyl, C1_10 
alkyl with an attached naphthyl substituted with K, phe-
nyl, phenyl substituted with K, naphthyl, naphthyl sub- 50 
stituted with K, C1_10 alkyl substituted with CONH2, 
C1_10 alkyl substituted with CONHR4 , C1_10 alkyl sub-
stituted with C02H, C1_10 alkyl substituted with C02R4 , 
CH2CH2SCH3, CH2-3-indolyl, CH2-2-thienyl, CH2-2-
furyl, CH2-3-furyl, CH2-2-imidazyl, C1_10 alkyl substi- 55 
tuted with G, C1_10 alkyl with an attached phenyl substi-
tuted with G, C1_10 alkyl with an attached naphthyl 
substituted with G, phenyl substituted with G, andnaph-
thyl substituted with G; 
R4 is selected from the group consisting of C1_10 alkyl and 60 
cl-10 alkyl substituted with phenyl; 
Q is selected independently from the group consisting of 
C1_10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy substituted 
with phenyl, and C1_10 alkyl-S- substituted with phe-
~; ~ 
G is selected independently from the group consisting of 
amidino (-C( NH)NH2), guanidino (-NHC(=NH) 
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NH2), isothiureido (-S-C(=NH)NH2), amino, C1_6 
alkylamino, c2-12 dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 





Rs is selected independently from the group consisting of 
cl-10 alkyl, c3-1S cyclized alkyl, cl-10 alkyl with a phe-
nyl group attached to the cl-10 alkyl, c3-1S cyclized alkyl 
with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
with an attached phenyl group disubstituted with K, 
cl-10 alkyl with an attached phenyl group trisubstituted 
with K, C3_1s cyclized alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, c3-1S cyclized alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached naphthyl group disubstituted with K, 
C1_10 alkyl with an attached naphthyl group trisubsti-
tuted with K, and C3_1s cyclized alkyl with an attached 
naphthyl group substituted with K; 
T is selected independently from the group consisting of 
OH, OR8 , NHR9 , and NR8 R9 ; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutanoic acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-C02H, alpha-aminoheptanoic 
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lanine, lysine substituted on the epsilon nitrogen with a 
biotinyl group, and hexafluoroleucine; 
R6 and R7 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, C3_20 cyclized alkyl, C1 _10 alkyl 
with a phenyl group attached to the cl-10 alkyl, cl-10 5 
alkyl with two phenyl groups attached to the cl-10 alkyl, 
C3_20 cyclized alkyl with an attached phenyl group, phe-
nyl, phenyl substituted with K, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached phenyl group disubstituted with K, 10 
cl-10 alkyl with an attached phenyl group trisubstituted 
with K, C1 _10 alkyl with two phenyl groups attached to 
the C1 _10 alkyl and substituted with K on the phenyl 
group, cl-10 alkyl with two phenyl groups attached to 
the C1_10 alkyl and disubstituted with K on the phenyl 15 
groups, C3_20 cyclized alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0]ring attached through nitrogen to the 
alkyl, C1_10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 20 
attached through nitrogen to the alkyl, cl-20 alkyl with 
an OH group attached to the alkyl, 
--CH2CH2CH20CH3, C1_10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 25 
C1_10 alkyl with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), -NH-CH2CH2-(3-in-
dolyl), cl-10 alkyl with an attached 2-furyl group, cl-10 
alkyl with an attached 3-furyl group, and C1_s alkyl with 
an attached phenyl and a hydroxyl attached to the C1 _s 30 
alkyl; and 
R8 and R9 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, phenyl, nitrophenyl, and C1_10 
alkyl substituted with phenyl. 
2. A method according to claim 1 wherein: 35 
R1 is selected from the group consisting of M 2-AA1 , 
M 2-AA2-AA1 , and M 2-AA3-AA2-AA1 ; 
M 2 is selected from the group consisting ofH, X--CO-, 
X-NH-CO-, Y-S02-, and Y ---0---CO-; 
X is selected from the group consisting of H, C1 _10 alkyl, 40 
C1_10 alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 45 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
Y is selected from the group consisting ofC1 _10 alkyl, C1_10 50 
alkyl substituted with J, phenyl, phenyl substituted with 
K, naphthyl, naphthyl substituted with K, C1_10 alkyl 
with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 55 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
J is selected from the group consisting ofC02H, OH, NH2, 60 
cl-10 alkoxy, cl-10 alkylamino, and cl-10 alkyl-0-
CO-; 
Kis selected from the group consisting ofC1 _10 alkyl, C1_10 
perfluoroalkyl, C1 _10 alkoxy, N02, CN, OH, C02H, 
amino, cl-10 alkylamino; 65 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
54 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-ami-





C02H, and NH2--CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1_10 alkyl 
substituted with CONH2, C1 _10 alkyl substituted with 
C02H, and C1_10 alkyl substituted with C02R4 ; 
R4 is selected from the group consisting ofC1 _10 alkyl and 
cl-10 alkyl substituted with phenyl; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , CONR6R7 , and CO-AA4 -
T; 
Rs is selected independently from the group consisting of 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl group 
substituted with K, C1 _10 alkyl with a naphthyl group 
attached to the cl-10 alkyl, and cl-10 alkyl with an 
attached naphthyl group substituted with K. 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, alpha-
aminobutanoic acid, epsilon-aminocaproic acid, orni-
thine, homoarginine, sarcosine, alpha-aminoheptanoic 
acid, NH2-CH(CH2-l-naphthyl)-C02H, NH2--CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2-cyclo-
hexyl)-C02H, NH2-CH(CH2-cyclopentyl)-C02H, 
NH2-CH(CH2-cyclobutyl)-C02H, and NH2--CH 
( CH2-cyclopropy l)-C02H; 
R6 and R7 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, C3_20 cyclized alkyl, C1 _10 alkyl 
with a phenyl group attached to the cl-10 alkyl, cl-10 
alkyl with two phenyl groups attached to the cl-10 alkyl, 
c3-20 cyclized alkyl with an attached phenyl group, phe-
nyl, phenyl substituted with K, C1_10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached phenyl group disubstituted with K, 
cl-10 alkyl with an attached phenyl group trisubstituted 
with K, C1 _10 alkyl with two phenyl groups attached to 
the cl-10 alkyl, cl-10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and substituted with Kon the 
phenyl group, cl-10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and disubstituted with K on 
the phenyl groups, C3_20 cyclized alkyl with an attached 
phenyl group substituted with K, C1 _20 alkyl with an OH 
group attached to the alkyl, -CH2CH2CH20CH3, C1_10 
alkyl with an attached 4-pyridyl group, C1 _10 alkyl with 
an attached 3-pyridyl group, C1_10 alkyl with an attached 
2-pyridyl group, C1 _10 alkyl with an attached cyclohexyl 
group, -NH--CH2CH2-( 4-hydroxyphenyl), -NH-
CH2CH2-(3-indolyl), C1 _10 alkyl with an attached 2-fu-
ryl group, cl-10 alkyl withanattached3-furyl group, and 
C1_s alkyl with an attached phenyl and a hydroxyl 
attached to the cl-S alkyl; and 
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R8 and R9 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, phenyl, nitrophenyl, and C1_10 
alkyl substituted with phenyl. 
3. A method according to claim 2 wherein: 
X is selected from the group consisting of H, C1 _10 alkyl, 5 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
group, C1_10 alkyl with an attached naphthyl group, and 
C1_10 alkyl substituted with C02H; 
AAv AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 10 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 15 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-ami-
nocaproic acid, ornithine, homoarginine, sarcosine, 
NH2---CH(CH2-l-naphthyl)-C02H, and NH2---CH 
(CH2-2-naphthyl)-C02H; 20 
Rs is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids with 
the L configuration, D configuration, or no chirality at 25 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 30 
histidine, phenylglycine, norleucine, norvaline, alpha-
aminobutanoic acid, epsilon-aminocaproic acid, citrul-
line, homoarginine, sarcosine, NH2---CH(CH2-l-naph-
thyl)-C02H, and NH2-CH(CH2-2-naphthyl)-C02H; 
R6 and R7 are selected independently from the group con- 35 
sisting ofH, C1_10 alkyl, C1 _10 alkyl with a phenyl group 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
groups attached to the cl-10 alkyl, phenyl substituted 
with K, C1 _10 alkyl with an attached phenyl group sub-
stituted with K, C1_10 alkyl with an attached phenyl 40 
group disubstituted with K, C1 _10 alkyl with two phenyl 
groups attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl and substituted 
with Kon the phenyl group, C1 _10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted with 45 
K on the phenyl groups, C3_20 cyclized alkyl with an 
attached phenyl group substituted with K, C1 _20 alkyl 
with an OH group attached to the alkyl, 
---CH2CH2CH20CH3, and C1 _s alkyl with an attached 
phenyl and a hydroxyl attached to the cl-S alkyl. 50 
4. A method according to claim 1 wherein: 
R1 is selected from the group consisting of M2-AA1 , 
M2-AA2-AA1 , and M2-AA3-AA2-AA1 ; 
M2 is selected from the group consisting ofH, X---CO-, 
X-NH-CO-, Y-S02-, and Y ---0---CO-; 55 
X is selected from the group consisting of H, C1 _10 alkyl, 
C1_10 alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 60 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 65 
Y is selected from the group consisting ofC1 _10 alkyl, C1_10 
alkyl substituted with J, phenyl, phenyl substituted with 
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K, naphthyl, naphthyl substituted with K, C1 _10 alkyl 
with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
J is selected from the group consisting ofC02H, OH, NH2, 
cl-10 alkoxy, cl-10 alkylamino, and cl-10 alkyl-0-
CO-; 
K is selected from the group consisting ofC1_10 alkyl, C1_10 
perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, C02H, 
amino, cl-10 alkylamino; 
AA1 , AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-ami-





C02H, and NH2---CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1 _10 alkyl, 
cl-10 alkyl substituted with Q, cl-10 alkyl substituted 
with phenyl, C1 _10 alkyl with an attached phenyl substi-
tuted withK, C1_10 alkyl substituted withnaphthyl, C1_10 
alkyl with an attached naphthyl substituted with K, and 
phenyl; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , CONR6R7 , and CO-AA4 -
T; 
Rs is selected independently from the group consisting of 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl group 
substituted with K, C1 _10 alkyl with a naphthyl group 
attached to the cl-10 alkyl, and cl-10 alkyl with an 
attached naphthyl group substituted with K. 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, alpha-
aminobutanoic acid, epsilon-aminocaproic acid, orni-
thine, homoarginine, sarcosine, alpha-aminoheptanoic 
acid, NH2-CH(CH2-l-naphthyl)-C02H, NH2---CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2-cyclo-
hexyl)-C02H, NH2-CH(CH2-cyclopentyl)-C02H, 
NH2-CH(CH2-cyclobutyl)-C02H, and NH2---CH 
( CH2-cyclopropy l)-C02H; 
R6 and R7 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, C3_20 cyclized alkyl, C1 _10 alkyl 
with a phenyl group attached to the cl-10 alkyl, cl-10 
alkyl with two phenyl groups attached to the cl-10 alkyl, 
c3-20 cyclized alkyl with an attached phenyl group, phe-
nyl, phenyl substituted with K, C1_10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached phenyl group disubstituted with K, 
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cl-10 alkyl with an attached phenyl group trisubstituted 
with K, C1 _10 alkyl with two phenyl groups attached to 
the cl-10 alkyl, cl-10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and substituted with Kon the 
phenyl group, cl-10 alkyl with two phenyl groups 5 
attached to the C1 _10 alkyl and disubstituted with K on 
the phenyl groups, c3-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an OH 
group attached to the alkyl, -CH2CH2CH20CH3, C1_10 
alkyl with an attached 4-pyridyl group, C1 _10 alkyl with 
10 
an attached 3-pyridy 1 group, C 1_ 10 alky 1 with an attached 
2-pyridyl group, C1 _10 alkyl with an attached cyclohexyl 
group, -NH-CH2CH2-(4-hydroxyphenyl), -NH-
CH2CH2-(3-indolyl), C1_10 alkyl with an attached 2-fu- 15 
ryl group, cl-10 alkyl withanattached3-furyl group, and 
C1_s alkyl with an attached phenyl and a hydroxyl 
attached to the cl-S alkyl; and 
R8 and R9 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, phenyl, nitrophenyl, and C1_10 20 
alkyl substituted with phenyl. 
5. A method according to claim 4 wherein: 
X is selected from the group consisting of H, C1 _10 alkyl, 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
group, C1_10 alkyl with an attached naphthyl group, and 25 
C1_10 alkyl substituted with C02H; 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro- 30 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid,epsilon-ami- 35 
nocaproic acid, ornithine, homoarginine, sarcosine, 
NH2---CH(CH2-l-naphthyl)-C02H, and NH2---CH 
(CH2-2-naphthyl)-C02H; 
Rs is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 40 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 45 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, alpha-
aminobutanoic acid, epsilon-aminocaproic acid, orni- 50 
thine, homoarginine, sarcosine, NH2-CH(CH2-l-
naphthyl)-C02H, and NH2---CH(CH2-2-naphthyl)-
C02H; and 
R6 and R7 are selected independently from the group con-
sisting ofH, C1_10 alkyl, C1 _10 alkyl with a phenyl group 55 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
groups attached to the cl-10 alkyl, phenyl substituted 
with K, C1 _10 alkyl with an attached phenyl group sub-
stituted with K, C1_10 alkyl with an attached phenyl 
group disubstituted with K, C1 _10 alkyl with two phenyl 60 
groups attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl and substituted 
with Kon the phenyl group, C1 _10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted with 
K on the phenyl groups, C3_20 cyclized alkyl with an 65 
attached phenyl group substituted with K, C1 _20 alkyl 
with an OH group attached to the alkyl, 
58 
---CH2CH2CH20CH3, and C1 _s alkyl with an attached 
phenyl and a hydroxyl attached to the cl-S alkyl. 
6. A method according to claim 1 wherein: 
R1 is selected from the group consisting of M 2-AA1 , 
M 2-AA2-AA1 , and M 2-AA3-AA2-AA1 ; 
M 2 is selected from the group consisting of H, X---CO-, 
X-NH-CO-, Y-S02-, and Y-0---CO-; 
X is selected from the group consisting of H, C1 _10 alkyl, 
C1_10 alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
Y is selected from the group consisting ofC1_10 alkyl, C1_10 
alkyl substituted with J, phenyl, phenyl substituted with 
K, naphthyl, naphthyl substituted with K, C1 _10 alkyl 
with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
J is selected from the group consisting ofC02H, OH, NH2, 
cl-10 alkoxy, cl-10 alkylamino, and cl-10 alkyl-0-
CO-; 
K is selected from the group consisting ofC1_10 alkyl, C1_10 
perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, C02H, 
amino, cl-10 alkylamino; 
AA1 , AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-ami-





C02H, and NH2---CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1_10 alkyl 
substituted with G, C1 _10 alkyl with an attached phenyl 
substituted with G, C1_10 alkyl with an attachednaphthyl 
substituted with G, phenyl substituted with G, andnaph-
thyl substituted with GU. 
G is selected independently from the group consisting of 
amidino (---C( NH)NH2), guanidino (-NHC(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), amino, and 
cl-6 alkylamino; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6, and CONR6R7 ; 
Rs is selected independently from the group consisting of 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl group 
substituted with K, C1 _10 alkyl with a naphthyl group 
attached to the cl-10 alkyl, and cl-10 alkyl with an 
attached naphthyl group substituted with K. 
R6 and R7 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, C3_20 cyclized alkyl, C1 _10 alkyl 
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with a phenyl group attached to the cl-10 alkyl, cl-10 
alkyl with two phenyl groups attached to the cl-10 alkyl, 
C3_20 cyclized alkyl with an attached phenyl group, phe-
nyl, phenyl substituted with K, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 5 
with an attached phenyl group disubstituted with K, 
cl-10 alkyl with an attached phenyl group trisubstituted 
with K, C1 _10 alkyl with two phenyl groups attached to 
the cl-10 alkyl, cl-10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and substituted with Kon the 10 
phenyl group, cl-10 alkyl with two phenyl groups 
attached to the C1 _10 alkyl and disubstituted with K on 
the phenyl groups, c3-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an OH 
group attached to the alkyl, -CH2CH2CH20CH3, C1_10 15 
alkyl with an attached 4-pyridyl group, C1 _10 alkyl with 
an attached 3-pyridy 1 group, C 1_ 10 alky 1 with an attached 
2-pyridyl group, C1 _10 alkyl with an attached cyclohexyl 
group, -NH-CH2CH2-(4-hydroxyphenyl), -NH-
CH2CH2-(3-indolyl), C1_10 alkyl with an attached 2-fu- 20 
ryl group, cl-10 alkyl withanattached3-furyl group, and 
C1_5 alkyl with an attached phenyl and a hydroxyl 
attached to the cl-5 alkyl; and 
R8 and R9 are selected independently from the group con-
sisting ofH, C1 _10 alkyl, phenyl, nitrophenyl, and C1_10 25 
alkyl substituted with phenyl. 
7. A method according to claim 5 wherein: 
X is selected from the group consisting of H, C1 _10 alkyl, 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
group, C1_10 alkyl with an attached naphthyl group, and 30 
C1_10 alkyl substituted with C02H; 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro 35 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-ami- 40 
nocaproic acid, ornithine, homoarginine, sarcosine, 
NH2---CH(CH2-l-naphthyl)-C02H, and NH2---CH 
(CH2-2-naphthyl)-C02H; 
R5 is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 45 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of ala-
nine, valine, leucine, isoleucine, praline, methionine, 50 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, alpha-
aminobutanoic acid, epsilon-aminocaproic acid, orni- 55 
thine, homoarginine, sarcosine, NH2-CH(CH2-l-
naphthyl)-C02H, and NH2---CH(CH2-2-naphthyl)-
C02H; and 
R6 and R7 are selected independently from the group con-
sisting ofH, C1_10 alkyl, C1 _10 alkyl with a phenyl group 60 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
groups attached to the cl-10 alkyl, phenyl substituted 
with K, C1 _10 alkyl with an attached phenyl group sub-
stituted with K, C1_10 alkyl with an attached phenyl 
group disubstituted with K, C1 _10 alkyl with two phenyl 65 
groups attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl and substituted 
60 
with Kon the phenyl group, C1_10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted with 
K on the phenyl groups, C3_20 cyclized alkyl with an 
attached phenyl group substituted with K, C1 _20 alkyl 
with an OH group attached to the alkyl, 
---CH2CH2CH20CH3, and C1 _5 alkyl with an attached 
phenyl and a hydroxyl attached to the cl-5 alkyl. 
8. The method of claim 1 wherein epoxide carbons 2 and 3 
have stereochemistry selected from the group consisting of 
cis; trans; R,R; S,S; R,S; and S,R. 
9. The method of claim 1, wherein said composition is 
substantially optically pure. 
10. The method of claim 1, wherien said composition is 
racem1c. 
11. The method of claim 9, wherein said composition sub-
stantially comprises a single optical isomer. 
12. A method of alleviation or stabilization of nerve degen-
eration in a manimal, wherein the nerve degeneration results 
from one or more of the following conditions: the presence of 
metabolic derangements,diabetes, uremia, central or periph-
eral ischemia, genetic susceptibility to nerve degeneration, 
and exposure to a neurotic agent, comprising: 
administering to a manimal a threpeutically effective 

















( o) Cbz-Leu-Glu-Thr-AAsp-(2S,3S)-EP-CON(CH2Ph)2, 
(p) Cbz-Ile-Glu-Thr-AAsp-(2S,3S)-EP-CON(CH2Ph)2, 
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60 (iii) Cbz-Ile-Glu-Thr-AAsp-(S,S)-EP-COOCH2Ph, 
(jjj) Cbz-Ile-Glu-Thr-AAsp-(R,R)-EP-COOCH2Ph, 
(kkk) Cbz-Ile-Glu-Thr-AAsp-(R,R)-EP-CONHCH2Ph, 
and a pharmaceutically acceptable salt thereof. 
13. A method of alleviation or stabilization of nerve degen-
65 eration in a mammal wherein the nerve degeneration results 
from one or more of the following conditions: the presence of 
metabolic derangements, diabetes, uremia, central orperiph-
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era! ischemia, genetic susceptibility to nerve degeneration, 
and exposure to a neurotoxic agent, comprising: 
administering to a mammal a therapeutically effective 
amount of a compound having the chemical formula 
Cbz-Asp-Glu-Val-AAsp-EP-COOEt. 
14. A method of treatment of nerve degeneration in a mam-
mal wherein the nerve degeneration results from one or more 
of the following conditions: the presence of metabolic 
derangements, diabetes, uremia, central or peripheral 
ischemia, genetic susceptibility to nerve degeneration, and 10 
exposure to a neurotoxic agent, comprising: 
administering to a mammal a therapeutically effective 
amount of a compound having the chemical formula 
Cbz-Asp-Glu-Val-AAsp-EP-COOCH2 C6H5 . 
15. Themethodofclaiml whereinsaidnervedegeneration 15 
results from one or more of the following conditions: stroke, 
Alzheimer's disease, Parkinson's disease, multiple sclerosis, 
neuropathies, Huntington's disease, dentatorubropallidoluy-
sian atrophy, spinocerebellar atrophy, spinal bulbar muscular 
atrophy, nerve degeneration associated with diabetes, nerve 20 
degeneration associated with uremia, nerve degeneration 
associated with a metabolic derangement, amyotrophic lat-
eral sclerosis, a motor neuron disease, genetic susceptibility 
to nerve degeneration, and exposure to a neurotoxic agent. 
16. The method of claim 1, wherein said nerve degenera- 25 
tion is selected from the group consisting of chronic degen-
eration of motor and or sensory neurons, idiopathic peripheral 
neuropathies, peripheral neuropathies due to genetic muta-
tions, peripheral neuropathies associated with diabetes, ure-
mia, rheumatologic diseases, liver diseases, or infections, 30 
axonal degeneration secondary to primary demyelinating dis-
orders, inflammatory demyelinating neuropathies, multiple 
sclerosis, and chronic spinal cord degenerations. 
17. The method of claim 1 wherein said nerve degeneration 
is the result of a neurotoxic agent. 35 
18. The method of claim 1, wherein the nerve degeneration 
is induced by an anti-cancer agent. 
19. The method of claim 17 wherein said neurotoxic agent 
comprises an agent causing microtubule stabilization or dis-
ruption. 40 
20. The method of claim 19, wherein said microtubule 
stabilizing agent comprises paclitaxel. 
21. The method of claim 1 wherein said nerve degeneration 
is inhibited by administration of the compound of claim 1 
prior to or simultaneous with administration of an anticancer 45 
drug. 
22. The method of claim 1, further comprising administer-
ing a therapeutically effective amount of a calpain inhibitor to 
the patient. 
23. The method of claim 22 wherein said cal pain inhibitor 50 
comprises a peptide alpha-keto amide. 
24. The method of claim 22 wherein said calpain inhibitor 
is Z-Leu-Abu-CONH-(CH2 k4-morpholinyl (AK295). 
25. The method of claim 22 wherein said calpain inhibitor 
is selected from the group consisting of: 55 
Z-Leu-Nva-CONHCH2 -2-pyridyl, 
Z-Leu-Abu-CONHCH2CH(OH)C6F5 , 
Z-Leu-Phe-CONH(CH2 ) 2Ph, 
Z-Leu-Abu-CONHCH2CH(OH)C6H4 -3-0C6H4 (3-CF3 ), 
Z-Leu-Abu-CONHCH2CH(OH)C6Hi 4-0CH2Ph), 60 
Z-Leu-Abu-CONHCH2CH(OH)C6Hi 4-0Ph), 
Z-Leu-Phe-CONHCH2 -2-quinolinyl, 
Z-Leu-Abu-CONH(CH2 ) 2 C6H4 (3-0CH3), 
Z-Leu-Abu-CONH(CH2 ) 2 C6H4 (4-0CH3), 
Z-Leu-Abu-CONHCH2CH( 0H)-1-C10H7 , 65 
Z-Leu-Phe-CONH( CH2 ) 3 -4-morpholiny I, 
Z-Leu-Abu-CONH(CH2 ) 2 C6H4 (2-0CH3 ), 
64 
Z-Leu-Abu-CONHCH2 -2-quinolinyl, 
Z-Leu-Abu-CONH(CH2 ) 3 -4-morpholinyl (AK295), 
Z-Leu-Abu-CONH(CH2 ) 2 -2-(N-methylpyrrole), 
Z-Leu-Phe-CONHCH2CH(OH)C6H4 -3-0C6Hi3-CF3 ), 
Z-Leu-Abu-CONH(CH2 ) 2C6H5 , 
Z-Leu-Phe-CONH-Et, 
Z-Leu-Abu-CONHCH2 CH(OC2 H5 ) 2 , 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-0Ph), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-0CH2 Ph), 
Z-Leu-Abu-CONHCH2 C6H5 , 
Z-Leu-Phe-CONH( CH2 ) 2 NH-biotiny I, 
Z-Leu-Phe-CONH( CH2 ) 3 -2-tetrahydroisoquinoliny I, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H3 (3,4-(0CH2 Ph)2 ), 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 (4-0CH3 ), 
Z-Leu-Nva-CONH( CH2 ) 3 -4-morpholiny I, 
Z-Leu-Abu-CONHCH2 - l-isoquinolinyl, 
Z-Leu-Abu-CONHEt, 




Z-Leu-Abu-CONH(CH2 ) 2 -3-indolyl, 
Z-Leu-Abu-CONH(CH2 ) 3 -2-tetrahydroisoquinolinyl, 
Z-Leu-Abu-CONHCH2 -2-tetrahydrofuryl, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 (4-N(CH3 ) 2 ), 
Z-Leu-Phe-CONH-n-Pr, 
Z-Leu-Abu-CONHCH2 CH(OH)-2-C10H7 , 
Z-Leu-Phe-CONH-Me, 
Z-Leu-Abu-CON HCH2CH(OH)C6Hi3-CF3 ), 
Z-Leu-Abu-CONH(CH2k 1-tetrahydroquinolinyl, 
Z-Leu-Abu-CON H(CH2 ) 2 C6H4 (4-0H), 
Z-Leu-Abu-CONHCH2 CH(OH)C6H2 (3,4,5-(0CH3 ) 3 ), 
Z-Leu-Phe-CONH( CH2 ) 3 -1-tetrahydroquinoliny I, 
Z-Leu-Abu-CONH(CH2 ) 2 -2-pyridyl, 
Z-Leu-Abu-CONHCH2---C6Hil,3,3-(CH3 ) 3 -5-0H), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi3-CF3), 
Z-Leu-Phe-CONHCH2CH(OH)C6H3 (3,4-(0CH2Ph)2 ), 
Z-Leu-Abu-CONH(CH2 ) 50H, 
Z-Leu-Abu-CONHCH2 CH(OCH3 ) 2 , 
Z-Leu-Phe-CONHCH2CH(OH)C6H4 -3-0C6H3 (3,4-Cl2 ), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi3-0Ph), 
Z-Leu-Phe-CONHCH2CH(OH)C6Hi 4-N(CH3 ) 2 ), 
Z-Leu-Abu-CONHCH2 -2-pyridyl, 
Z-Leu-Abu-CONH(CH2 ) 20(CH2 ) 20H, 
Z-Leu-Phe-CONHCH2 -2-pyridyl, 
Z-Leu-Abu-CONH(CH2 ) 2NH-biotinyl, 
Z-Leu-Abu-CONHCH2 -C6H 1 u 
Z-Leu-Phe-CONHCH2CH(OH)C6F 5 , 
Z-Leu-Abu-CONHCH2 -2-furyl, 
Z-Leu-Abu-CONH(CH2 ) 3C6H5 , 
Z-Leu-Abu-CONH(CH2 ) 20H, 
Z-Leu-Abu-CONHCH2 CH(OH)C6H4 (3-0Ph), 





Z-Leu-Abu-CONHCH2 C6H3 (3,5-(0CH3 ) 2 ), 
Z-Leu-Nva-CONHCH2 CH(OH)Ph, 
Z-Leu-Abu-CONHCH2 -8-caffeiny I, 
Z-Leu-Abu-n-Pr, 
Z-Leu-Abu-CONHCH2 -3-pyridyl, and 
Z-Leu-Phe-CONHCH2Ph. 
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26. The method of claim 22 wherein said calpain inhibitor 
is selected from the group with the formula: 
M 1-AA2 -AA1-CO-NR3R, 
a pharmaceutically acceptable salt or prodrug thereof, 5 
wherein 
M1 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, 
X2N--CO-, X-NH--CS-, X2N-CS-, 
X-NH-S02-, X2N-S02-, X-CO-, X-CS-, 10 
X-, Y-S02-, Y---0-CO-, Y---0---CS-, mor-
pholine-CO-, and biotinyl; 
X is selected from the group consisting of H, C1_10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl sub-
stituted with J, cl-10 fluoroalkyl substituted with J, 1-ad- 15 
mantyl, 9-fluorenyl, phenyl, phenyl monosubstituted 
with K, phenyl disubstituted with K, phenyl trisubsti-
tuted with K, naphthyl, naphthyl monosubstituted with 
K, naphthyl disubstituted with K, naphthyl trisubstituted 
withK, C1_10 fluoroalkyl with an attached phenyl group, 20 
cl-10 alkyl with an attached phenyl group, cl-10 alkyl 
with two attached phenyl groups, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached naphthyl group, cl-10 alkyl 25 
with an attached naphthyl group substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 
alkyl with an attached phenoxy group substituted with K 
on the phenoxy group, and C1_10 alkyl monosubstituted 
withM2; 30 
Y is selected from the group consisting ofC1_10 alkyl, C3_15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl monosubstituted with K, 
phenyl disubstituted with K, phenyl trisubstituted with 35 
K, naphthyl, naphthyl monosubstituted withK, naphthyl 
disubstituted with K, naphthyl trisubstituted with K, 
cl-10 fluoroalkyl with an attached phenyl group, cl-10 
alkyl with an attached phenyl group, cl-10 alkyl with two 
attached phenyl groups, C1_10 alkyl with an attached 40 
phenyl group substituted with K, C1_10 alkyl with two 
attached phenyl groups substituted with K, C1_10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 45 
attached phenoxy group substituted with K on the phe-
noxy group, M2, and C1_10 alkyl monosubstituted with 
M2; 
M2 is selected from the group consisting of 2-furyl, 2-tet-
rahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazi- 50 
nyl, 2-quinolinyl, 1-tetrahydroquinolinyl, 1-isoquinoli-
nyl, 2-tetrahydroisoquinolinyl, and -N(CH2CH2)20; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, 
C2_12 dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl- 55 
0---CO-NH-, C1_10 alkyl-S-, and -N(CH2CH2)2 
O; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, 
CN, OH, C02H, amino, C1_10 alkylamino, C2_12 dialky- 60 
!amino, C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 
alkyl-S-, and -N(CH2CH2)20; 
66 
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutanoic acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)--C02H, alpha-aminohep-
tanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, 
NH2-CH(CH2-2-naphthyl)-C02H, NH2-CH(CH2-
cyclohexyl)-C02H, NH2-CH(CH2-cyclopentyl)-
C02H, NH2--CH(CH2-cyclobutyl)-C02H, NH2--CH 
(CH2-cyclopropyl)-C02H, trifluoroleucine, 
4-fluorophenylalanine, lysine substituted on the epsilon 
nitrogen with a biotinyl group, hexafluoroleucine, and 
NH2-CHR
2 -C02H; 
R2 is selected from the group consisting of C1_10 branched 
and unbranched alkyl, C1_10 branched and unbranched 
cyclized alkyl, and C1_10 branched and unbranched fluo-
roalkyl; 
R3 and R4 are selected independently from the group con-
sisting of 
a) H1_20 alkyl, C1_20 cyclized alkyl, C1_20 alkyl with a phe-
nyl group attached to the cl-20 alkyl, cl-20 cyclized alkyl 
with an attached phenyl group, C1_20 alkyl with an 
attached phenyl group monosubstituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with 
K, C1_20 alkyl with an attached phenyl group trisubsti-
tuted with K, C1_20 cyclized alkyl with an attached phe-
nyl group monosubstituted with K, C1_10 alkyl with a 
morpholine [-N(CH2CH2)0] ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a piperidine ring 
attached through nitrogen to the alkyl, C1_10 alkyl with a 
pyrrolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
--CH2CH20CH2CH20H, C1_10 with an attached 4-py-
ridyl group, cl-10 with an attached 3-pyridyl group, 
cl-10 with an attached 2-pyridyl group, cl-10 with an 







R5 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, pentafluorophenyl, 
AA 1 andAA 2 side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chirality 
at the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, pro line, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
1-naphthyl, 1-naphthyl monosubstituted with J, 1-naphthyl 
65 disubstituted with J, 2-naphthyl, 2-naphthyl monosubstituted 
with J, 2-naphthyl disubstituted with J, 2-pyridyl, 2-quinoli-
nyl, and 1-isoquinolinyl; 
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R6 is selected from the group consisting ofC1_4 alkyl, C1 _4 
alkyl substituted with phenyl, phenyl, and phenyl sub-




R7 is selected from the group consisting of2-furyl, 2-furyl 5 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 10 
J, 27. A method of alleviation or stabilization of nerve degen-



















administering to a mammal therapeutically effective 
amounts of a combination of a calpain inhibitor and a 
caspase inhibitor; 
wherein the caspase iinhibitor comprises either Cbz-Asp-
Glu-Val-AAsp-EP-COOEt or Cbz-Asp-Glu-Val-AAsp-
EP-COOCH2C6H5, or both and wherein the inhibitor 
comprises Z-Leu-Abu- CONH-(CH2k4-morpholinyl 
(AK295). 
28. A method of alleviation or stabilization of nerve degen-
eration in a mammal, comprising: administering to a mammal 
therapeutically effective amounts of a combination of a 
cal pain inhibitor and a caspase inhibitor wherein the caspase 
25 inhibitor comprises Cbz-Asp-Glu-Val-AAsp-EP-COO Et and 
wherein the calpain inhibitor comprises Z-Leu-Abu-CONH-
(CH2k4-morpholinyl (AK295). 
29. The method of claim 12, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
30 to the patient. 
30. The method of claim 13, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
31. The method of claim 14, further comprising adminis-
35 tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
40 
32. The method of claim 15, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
33. The method of claim 16, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
34. The method of claim 17, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
45 to the patient. 
35. The method of claim 18, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
36. The method of claim 19, further comprising adminis-
50 tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
55 
37. The method of claim 20, further comprising adminis-
tering a therapeutically effective amount of a calpain inhibitor 
to the patient. 
38. The method of claim 21, wherein a calpain inhibitor is 
administered prior to or simultaneously with the anticancer 
drug. 
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